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1.  Introduction 
 
1.1.   The Cytokine IL-6 and gp130-dependent signalling 
 
Interleukin 6 (IL-6) was originally identified as a B-cell differentiation factor 1-3 
and is now known as a multifunctional cytokine that regulates hematopoiesis and 
inflammation 4. Most IL-6 is produced by macrophages or kupffer cells in the liver 5,6. 
The IL-6 family of cytokines forms a subfamily of cytokines 7, which include leukemia 
inhibitor factor (LIF), ciliary neurotrophic factor (CNTF), oncostatin M (OSM), IL-11, 
cardiotrophin-1 (CT-1) and cardiotrophin-like cytokine (CTC), neuropoietin (NPN) and 
has recently been enlarged by the addition of the newly characterized IL-27 and IL-
31 8-10. The topography of these helices is different for each cytokine, resulting in the 
specifity with which a cytokine interacts with gp130 and its cognate receptor. The 
prototypical IL-6 receptor (IL-6R) is composed of an 80kDa α-subunit, IL-6Rα, that 
complexes with two signal-transducing gp130 α-subunits after binding of IL-6. This 
constitutes the active ligand-receptor complex. Dimerization of the α-subunits is 
essential for receptor activation 11. Only IL-6 and IL-11 of the IL-6-like cytokines 
signal via a gp130 homodimer that is additionally bound to either an IL-6 specific 
receptor (gp80, IL-6R) or an IL-11 (IL-11R). Thus, IL-6 and IL-11 are totally 
dependent on gp130 for signal transduction. The remaining IL-6 like cytokines 
interact with a receptor containing one subunit of gp130 and either a LIF receptor 
(LIF, CT-1, OSM, CNTF, CLC and NPN) or an OSM receptor (OSM, IL-31). Recent 
studies demonstrated that IL-27 signals via gp130 and a ligand-binding coreceptor, 
WSX-1 8. α-subunits are only known for IL-6, IL-11 and CNTF. These ligands first 
bind their α-subunits and subsequently induce homo- or heterodimerization of the 
signalling α-subunits. LIF, OSM and CT-1 bind directly to their signalling subunits and 
induce heterodimerization 12-20. Since gp130 is expressed ubiquitously during 
development and by a variety of immune and non immune cells in adult animals, 
distinct functions and tissue tropisms of gp130-associated cytokine receptors are 
determined by the tightly regulated expression of the ligand specific α-subunits 21. 
Although gp130 is ubiquitious, cell type specifity of IL-6 cytokine family members is 
achieved because gp80 (IL-6R) expression is cell type specific. 
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1.1.1.  Activation of JAK 
 
The resulting IL-6/gp130 receptor complex undergoes a conformational 
change that allows for the interaction and activation of a Janus kinase (JAK), an 
intracellular tyrosine kinase 22-25. Interaction of gp130 with JAK1 is essential for IL-6 
signalling 26,27. As explicitly described in Figure 1, the activation of JAK results in 
tyrosine phosphorylation of gp130 at several sites and finally in the induction of two 
major signal transduction pathways through the cytoplasmic domain of gp130: first 
signal transduction via the STAT3 pathway and second the mitogen activated protein 
kinase (MAPK) signal transduction pathway 28.  
 
 
Figure 1: Activation of gp130-dependent intracellular signalling cascades. Signalling cascades 
are shown from IL-6-bound gp130 homodimers. ß-subunit dimerization and tyrosine (Y) 
phosphorylation by the constitutively associated JAK family kinases is an absolute requirement for 
subsequent activation of the two major intracellular signalling cascades, SHP2/Erk-MAPK and 
STAT1/3. Receptor-bound SHP2 is Y-phosphorylated by JAKs and then binds to the adapter protein 
growth factor receptor binding protein 2 (Grb2), constitutively associated with SOS and Ras triggers 
Erk activation. Phosphorylation of the second most membrane proximal tyrosine Y757 is linked to the 
Ras/Erk pathway as well as to negative regulation of gp130 signalling by SOCS3. Secondly STAT1/3 
bound to the phosphorylated tyrosines Y765, Y812, Y904, Y914 (the YxxQ signalling motifs), become 
phosphorylated by JAKs, form STAT dimers and translocate to the nucleus. 
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1.1.2. Signal transducers and activators of transcription (STAT) 
signalling 
 
Signal transducer and activator of transcription 3 (STAT3) was first described 
as a DNA-binding activity from IL-6 stimulated hepatocytes that interacted with a 
palindromic sequence within the promotor region of several acute phase genes 21,25-
28
. The STAT family of transcription factors contains seven mammalian members, 
designated STAT1, 2, 3, 4, 5a, 5b and 6 respectively 27. STAT3 shows homology to 
other STAT proteins, having a conserved amino-terminus involved in tetramerization, 
a DNA-binding domain with a sequence specificity for a palindromic sequence similar 
to that of STAT1, a SH2 domain which is involved in receptor recruitment, as well as 
STAT dimerization, and a carboxy terminal transactivation domain.  
STAT3 is activated by tyrosine phosphorylation at a single site (Y705) and 
serine phosphorylation at a MAPK consensus site within its transactivation domain. 
Tyrosine phosphorylation mediated by JAK is required for STAT3 dimerization, 
nuclear translocation and DNA binding 23,29-31.  
 
 
1.1.3. Mitogen activated protein kinase (MAPK) signalling 
 
Stimulation of gp130 leads not only to STAT signalling but also to activation of 
the mitogen activated protein kinase (MAPK) cascade. The current evidence 
suggests that SHP2 interacts with gp130 at human tyrosine 759 (murine Y757) and 
undergoes tyrosine phosphorylation and activation by JAK1 leading to recruitment of 
Grb2-SOS (growth factor receptor boundprotein/son of sevenless). Grb2-SOS 
activates Ras, which in turn leads to Raf-MEK-MAPK (particularly extracellular signal-
regulated kinase (Erk) 1/2) activation. MAPK signalling is a critical component of the 
proliferative response of cells including hepatocytes 32.  
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1.1.4. Negative regulation by the suppressor of cytokine 
signalling 3 (SOCS3)   
 
The duration and intensity of gp130 signalling appears to be limited by 
transcriptional induction of negative regulatory proteins of the suppressor of cytokine 
signalling (SOCS) family, including cytokine-inducible SH2 protein (CIS) and SOCS 
1-7 that impair Jak-mediated substrate phosphorylation 33. Transcripts encoding CIS 
and SOCS1-3 are upregulated in response to cytokine stimulation. SOCS proteins 
therefore form part of a classical negative feedback loop. SOCS family members 
modulate signalling by several mechanisms, which include inactivation of JAKs, 
blocking access of the STAT proteins to receptor binding sites and ubiquitination of 
signalling proteins and their subsequent targeting to the proteasome 34,35. SOCS3 is 
a specific inhibitor of IL-6 signalling containing SH2 domains allowing them to interact 
with and block the kinase activity of JAKs 36. In addition, SHP2 also functions as a 
phosphatase that interacts with JAK and mediates MAPK activation but may also 
terminate the signal by dephosphorylation of JAK, gp130 and STAT3. SOCS3 may 
also bind specifically to gp130 tyrosine residues, blocking gp130 signalling. Notably, 
the SHP2 tyrosine phosphatase competes with SOCS3 to bind to the membrane-
proximal tyrosine Y757 in murine gp130, thus implicating this residue in the negative 
regulation of gp130 signalling 37. SOCS3 protein levels are dynamically upregulated 
by IL-6 within the liver and could critically downregulate IL-6 signal 38.  
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1.2.  The Liver 
 
1.2.1.  Physiology and central function of the liver 
 
The liver, which is the largest glandular organ of the mammalian body, plays a 
central role in metabolic homeostasis. It serves as the primary regulatory site for 
energy metabolism, synthesizes essential proteins, enzymes and co-factors for 
digestion and regulation of metabolic functions. Essential functions are formation and 
secretion of bile acid, regulation of ammonia, iron and bicarbonate homeostasis and 
synthesis of most plasma proteins. Additionally, the liver has an important role as the 
major detoxifying organ, eliminating a variety of endogenous and exogenous 
compounds. Finally, providing important immunologic function the liver is the central 
organ for phagocytosis of macromolecules and microorganisms such as bacteria. As 
the first line of defence against ingested toxins and many infectious agents, the liver 
has evolutionarily conserved responses including the ability to regenerate and to 
protect itself against injury. Due to the extensive functions, the ultrastructure of the 
liver consists of various cell populations of complex organisation. The most abundant 
cell type by mass and number are hepatocytes constituting 80% of the lobular 
parenchyma and form the biggest group of the cell population in the liver. The shape 
of hepatocytes is irregular polyhedral with a size ranging from 20 to 30 µm 39,40. The 
hepatocyte is a polarized epithelial cell consisting of three different specialized 
membrane domains: the basolateral (sinusoidal), a specialized bile canalicular and 
the intercellular domain, containing tight junctions, gap junctions and desmosomes. 
In dependence on age, metabolic load, location of the cell and regenerative activity 
hepatocytes vary in shape and size. The nucleus of the hepatocyte constitutes 5 to 
10 percent of cell volume, is spherical in shape and contains one or more prominent 
nucleoli. Twenty-five percent of hepatocytes are binucleate. The nuclear size is 
correlated with nuclear ploidy; approximately 15% of hepatocytes are tetraploid 41.  
Hepatocytes develop from the primitive precursor cell called hepatoblast derived from 
endodermal outgrowth of the hepatic diverticulum, which supposed to give rise to the 
hepatocyte and parenchymal cells. Characteristic for the hepatoblast is the synthesis 
of α-fetoprotein (AFP) starting in the human liver as early as day 19. In contrast, 
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expression of the most prominent liver-specific secreted protein albumin starts later. 
The induction of albumin increases in parallel with the decrease of AFP gene 
expression. As the most typical marker for early stages of liver development the 
expression of AFP stops almost completely after birth 42-44. 
The liver also consists of nonparenchymal cells, like resident immune cells 
including Kupffer cells, NK-lymphocytes, T-lymphocytes and the population of 
mesenchymal cells, providing stellate cells, liver myofibroblasts and last but not least 
specialized cells like sinusoidal endothelial cells and cholangiocytes. The present 
work basically focuses on the role of hepatocytes on molecular level during liver 
regeneration, homeostasis and infection. Therefore other cells of the liver, not 
detracting their importance are just mentioned and not discussed in detail. 
 
 
1.2.2. Regulation of liver homeostasis  
 
1.2.2.1. The acute phase response 
 
Maintenance of liver homeostasis is achieved by a number of mechanisms 
strongly involving the liver. The liver responds to challenges, like tissue injury or loss, 
infection and intoxication with coordinated systemic and metabolic changes, like 
inflammatory reactions, collectively known as the acute phase 45-49. The purposes of 
these responses are to restore homeostasis. Characteristic for the acute phase 
response is fever, neutrophilia, changes in lipid metabolism, hypoferraemia, 
increased gluconeogenesis, increased protein catabolism, hormonal changes and 
expression of the characteristic acute phase proteins. Induction of serum acute 
phase proteins after damaging challenges is the most prominent feature of the acute 
phase response 46. Acute phase proteins are synthesized almost exclusively in the 
liver and serve important functions in restoring homeostasis after infection or 
inflammation, including haemostatic functions (e.g., fibrinogen), microbicidal and 
phagocytic functions (e.g. complement components, C-reactive protein), 
antithrombotic properties and antiproteolytic actions. During inflammation acute 
phase proteins are induced via the gp130 receptor resulting in activation of STAT3. 
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The acute phase proteins include SAA (serum amyloid A), CRP (C-reactive protein; 
human), complement C3, haptoglobin (rodents), α1-acid glycoprotein fibrinogen, 
haptoglobin (human), α1-antichimotrypsin, α1-antitrypsin, α2-macroglobin (rat) and 
hepcidin 50,51. Inactivation of STAT3 led to significant impairment of the acute phase 
response 52. Wuestefeld et al. showed that induction of the acute phase protein SAA 
was completely blunted in mice lacking the gp130 receptor 53. This result suggested 
that acute phase response mediated by SAA depends on gp130 signalling and 
subsequent activation of STAT3. In contrast IL-6 knockout mice were showing 
normal levels of SAA induction 54. These findings exhibit the importance of gp130-
dependend signalling for induction of the acute phase response, independent of the 
cytokine IL-6.  
 
1.2.2.2. Iron homeostasis 
 
Another focus of the present work is related to iron homeostasis. Providing a 
major site in iron homeostasis, the liver stores approximately 40% of the body iron 55, 
mainly located (98%) in the hepatic parenchymal cells 56. The liver also regulates iron 
trafficking into and around the body through the production of the peptide hepcidin. 
This hepatic peptide of 25 amino acids is an antimicrobial molecule produced by the 
liver in response to inflammatory stimuli and iron and serves as the principal 
regulator of systemic iron homeostasis 57-60. Hepcidin controls plasma iron 
concentration and tissue distribution of iron by inhibiting intestinal iron absorption, 
iron recycling by macrophages, and iron mobilization from hepatic stores. Hepcidin 
acts by inhibiting cellular iron efflux through binding to and inducing the degradation 
of ferroportin (FPN), the only known cellular iron exporter. It has been recently 
shown, that hepcidin binds to FPN in cultured cells stably expressing FPN, and, 
following complex internalization, leads to FPN degradation 61. Moreover, hepcidin is 
highly concentrated in organs expressing FPN 62. This implies decreased FPN 
expression and reduced iron release from cells such as enterocytes and 
macrophages, whenever circulating hepcidin levels are high, namely, inflammation 
58,63
 and iron overload 50,64,65. Synthesis of hepcidin is homeostatically increased by 
iron loading and decreased by anemia and hypoxia. It is also elevated during 
infections and inflammation, causing a decrease in serum iron levels and contributing 
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to the development of anemia of inflammation, probably as a host defence 
mechanism to limit the availability of iron to invading microorganisms. On the other 
hand, hepcidin deficiency appears to be the ultimate cause of most forms of 
hemochromatosis, either due to mutations in the hepcidin gene itself or due to 
mutations in the regulators of hepcidin synthesis 66. From transgenic mouse models 
carrying genetic disruptions of the hepcidin gene develop iron overload resembling 
hemochromatosis 67,68. Transgenic animals over-expressing hepcidin die perinatally 
due to severe iron-deficiency anemia occurring in the context of reticuloendothelial 
cell iron overload 69. In vivo injection of hepcidin into mice significantly reduced 
mucosal iron uptake and transfer to the carcass, independently on iron status or 
presence of the hemochromatosis protein HFE 70, or induces hypoferremia in 
humans 71.  
Other proteins that play important roles in iron metabolism of hepatocytes are 
ceruloplasmin (Cp) 72, haptoglobin 73 and hemopexin 74. Since hemopexin and 
haptoglobin are also described as acute phase reactants, their expression is known 
to be stimulated by proinflammatory cytokines. The hepatocyte also plays a major 
role in regulating body iron homeostasis as it is the main site of expression of the 
regulatory proteins HFE and transferring receptor 2 (TfR2) 75. Both hepatocytes and 
Kupffer cells are known to dominate iron metabolism in the liver. To date, it is not 
fully known, if hepcidin and HFE are also expressed in Kupffer cells. 
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1.3.  Regulation of liver regeneration 
 
1.3.1. The cell cycle 
 
Regulation and precise control of the cell cycle is central to normal 
proliferation and differentiation. The cell cycle is basically divided in two events: 
mitosis and cytokinesis 76. Replication of the DNA in each chromosome, followed by 
acurate separation is accomplished during M phase (nuclear division) of the cell 
cycle 76. The interphase, situated between two M phases, is divided into the three 
remaining phases of the cell cycle: during S phase (S = synthesis) the nuclear DNA 
is replicated. The two remaining phases of the cell cycle occur between M and S 
phases and are designated as gap phases and constitute as checkpoints for the cell 
77
. The interval between the completion of M phase and beginning of S phase is G1 
phase (G = gap), while G2 phase is the interval between end of S phase and 
beginning of the M phase. Checkpoints of the cell cycle are in late G1 phase 
(restriction point), at end of G2 phase (G2/M checkpoint) or during mitosis (mitotic 
spindle checkpoint) (Figure 2). Gaps during the interphase are fronting long-term 
mitotic inactivation of the cell during the so called G0 phase 78,79. Transition through 
cell cycle is tightly controlled by a number of cellular proteins, called cyclin-
dependent kinases (Cdks). They are regulated by their regulatory subunits termed 
cyclins and Cdk inhibitors. Typically, protein levels of cyclins peak during cell cycle in 
a cyclic manner. 
The process of DNA synthesis is initiated and regulated by four families of 
regulatory cyclins (cyclin D, E, A and B) combined with a limited number of Cdks 
(Cdk4/6, Cdk2 and Cdk1). The D family of cyclins transduce mitogenic signals 
through their activation of Cdk4 and Cdk6 allowing activation of the next two 
complexes 80-82, through synthesis of cyclin E1 and E2 and cyclin A. The E type 
cyclins bind to Cdk2 and initiate DNA replication 81,83-85. Cyclin A also binds to Cdk2 
and is important for progression through S phase though they also bind Cdk1 in the 
later S phase and during G2 phase 86,87. Finally, entrance into mitosis involves 
activation of Cdk1 by the cyclin B family members 80,88,89 (Figure 2). 
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Figure 2: Cell cycle phases are coordinated by cyclin-dependent kinases (Cdks) and their 
regulatory subunits, the cyclins. The activities of cyclin-Cdk complexes depend on the 
phosphorylation status of Cdks and the expression level of cyclins. Phase-specific cyclin-Cdk 
complexes confer specificity and orderly progression through the cell cycle. Initially, increasing 
accumulation of cyclin D-Cdk4/6 and cyclin E-Cdk2/3 complexes are regulating the transition through 
the G1 and S phases and overcoming the restriction point. The subsequent G2-M transition is 
regulated by cyclin A-Cdk1/2 and cyclin A/B-Cdk1 complexes with a crucial function in passing G2/M- 
and mitotic spindle checkpoint. Drawing was assumed from the PhD thesis of N.H. Zschemisch 90. 
 
 
1.3.2. Partial hepatectomy (PH) as an experimental model for 
liver regeneration  
 
The liver has a high capacity to regenerate following injury such as partial 
surgical resection, which has been widely used as an experimental model for 
studying cell cycle regulation. The hepatocyte is a unique cell that is highly 
differentiated but remains capable of replication. Under normal and healthy 
conditions hepatocytes are at the G0 stage of the cell cycle. In response to stimuli 
due to tissue loss, these cells respond rapidly and proliferate. During this 
regenerative process cells maintain their major morphologic features, have an active 
urea cycle and continue to metabolize drugs and synthesize albumin. This 
extraordinary capacity for compensatory growth in response to conditions induced by 
toxic injury and physical or infectious cell loss is a tightly regulated process of both 
hypertrophy (increase in cell size or protein content during the prereplicative stage) 
and hyperplasia (increase in the number of cells). Involving different liver cell 
populations liver regeneration is sensitively regulated by the interplay between 
growth factors, cytokines, extracellular matrix components and other regulators 91-94. 
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Although the adult liver contains cells with "stem-cell" properties, regeneration is 
accomplished by replication of mature hepatocytes.  
The most commonly used model demonstrating proliferative capacity of 
hepatocytes during liver regeneration is the partial hepatectomy in rats and mice as 
described by Higgins and Anderson (1931). This model allows the analysis of cell 
proliferation in vivo and enhances the understanding of regulating cyclins and Cdks 
and the arrangement of protein complexes. During liver regeneration following PH, 
quiescent hepatocytes enter the G1 phase and undergo one or two rounds of cell 
cycle as described in. DNA synthesis starts at 24 hours in mice and peak of mitosis 
occurs at 48 hours. Seven days after PH , all liver cells have divided once or twice 
and the liver organ has recovered within approximately 10% (plus or minus) of the 
original hepatic mass before surgery 92,95,96.  
In general terms, the replicative response of quiescent hepatocytes after 
partial hepatectomy involves multiple steps, each requiring different sets of controls 
and circuits. These steps start by DNA binding of transcription factors such as NFκB 
or STAT3 and the rapid activation of proto-oncogenes and other genes that encode 
proteins of diverse functions (immediate early genes). Initiation of the regenerative 
response depends on IL-6 and TNFα priming quiescent hepatocytes for progressing 
G0/G1 transition of the cell cycle 97,98. These initial events sensitize hepatocytes to 
growth factors that subsequently drive quiescent cells to G1 phase of the cell cycle. 
Progression of primed/competent hepatocytes through G1 and subsequent 
replicative cycling is depending on hepatocyte growth factor (HGF) and transforming 
growth factor-alpha (TGF-α) signalling. Thereafter proliferation process seems to 
proceed through the cell cycle including G1/S and G2/M restriction points 
autonomously under the control of cyclins and cyclin-dependent kinases 99-102. Within 
a few hours after PH hypertrophy of hepatocytes begins with accumulation of amino 
acids and triglycerides and activation of enzymes that are associated with 
proliferative activity. Increased DNA synthesis is associated initially with hyperplasia 
of hepatocytes, and then other cells, which begins in the periportal region and 
spreads in a wave-like fashion to the pericentral region of the lobule.  
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1.3.3.       The role of gp130 signalling during liver regeneration 
  
Studies in knockout mice studies indicated that normal liver regeneration after 
partial hepatectomy requires IL-6 5,103. Following partial hepatectomy, IL-6-/- livers 
show impaired liver regeneration characterized by liver necrosis and failure, a 
blunted DNA synthesis in hepatocytes, and discrete G1 phase abnormalities 
including absence of STAT3 activation and selective abnormalities in gene 
expression. Pretreatment of IL-6-/- mice with IL-6 rescues STAT3 binding, gene 
expression, and hepatocyte proliferation to almost normal level and prevents liver 
damage. This established IL-6 as a critical component of the regenerative response 
following partial hepatectomy. Most of the actions mediated by IL-6 occur within the 
first few hours post hepatectomy and lead to progression through early to mid phases 
of G1 and ultimately to DNA synthesis and mitosis. In recent years it has been 
demonstrated that IL-6 does not directly control hepatocyte proliferation after PH, but 
activates signalling pathways that are protective for the progression of regeneration 
53
. Subsequent studies demonstrated that IL-6 protects from apoptosis after partial 
hepatectomy and plays a major role during the mitogenic response 53,104,105. For the 
normal proliferative response post hepatectomy, TNFα is required to induce IL-6. 
DNA synthetic defects in TNF receptor knockout mice can be corrected by IL-6 106. 
Almost 40% of the immediate early genes activated during liver regeneration are 
regulated in part by IL-6 107. IL-6 treatment of IL-6-/- mice in the absence of 
hepatectomy induces a much smaller set of genes in the liver, suggesting that IL-6 
cooperates with other hepatectomy-induced factors to activate the large number of 
genes.  
As mentioned before, IL-6 activates two major pathways during liver 
regeneration through gp130, STAT3 and MAPK. The constitutive knockout of STAT3 
results in embryonic lethality. To test the contribution of STAT3 to growth response 
mediated by IL-6, conditional liver-specific STAT3 knockouts have been analyzed. In 
these mice entire STAT3 activation in hepatocytes is blunted. After hepatectomy 
hepatocyte DNA synthesis was impaired in these knockout animals and the observed 
abnormalities in immediate-early gene activation largely correlated with those seen in 
IL-6-/- livers 108. As described in the literature by Taub et al., major effects on STAT3 
target genes were observed, as well as misregulation of the cell cycle and reduced 
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proliferation 108. Conditional knockout of gp130 within the liver had less impact on 
hepatocyte DNA synthesis post hepatectomy as expected from data with IL-6 and 
STAT3 knockout mice. However, defects in cyclin E and A expression were observed 
in gp130-deleted livers after liver resection, indicating that gp130 is important for 
normal cell cycle progression 53. Another study 105 indicated that IL-6 was primarily 
required for survival after partial hepatectomy. However, even in this study 
mitogenesis was impaired in IL-6 knockout livers at the early regenerative stages, 
consistant with Cressmann et al. 5. Studies in which IL-6 has been overexpressed in 
the liver also defines IL-6 as a major regulator of hepatocyte proliferation. Studies in 
which soluble receptor IL-6R was overexpressed support the importance of this 
molecule in hepatic growth mediated by IL-6 109-111. Another study implicated that the 
need for additional growth factors may be overcome by high levels of IL-6 112. In 
summary, it is accepted that IL-6 has pleiotropic effects in the liver and is required for 
a normal integrated response to partial hepatectomy, which requires acute phase 
response, suppression of apoptosis and induction of hepatocyte proliferation 113. 
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1.4.  Sepsis 
 
Sepsis remain the most common cause of death within intensive care units 114. 
In particular, sepsis and septic shock caused by gram-positive bacteria such as 
streptococci and staphylococci have become an increasingly important clinical 
problem 115-117. Recent epidemiological studies from North America found that the 
incidence of sepsis was approximately 3 cases per 1000 population, which translates 
into an annual burden of approximately 750.000 cases. The overall mortality is 
approximately 30%, rising to 40% in the elderly. Toxic shock syndromes are among 
the most acute and most severe forms of septic shock and the mortality can be as 
high as 50%.  
The liver is affected early during progress of sepsis, is forming an early line of 
defence and therefore can provide a potential target for early treatment. Getting in 
contact with endotoxin of gram-positive bacteria via the portal vein, Kupffer cells 
accomplish to neutralization. Due to disturbances of microcirculation, burden of 
endotoxin in the liver become dramatically elevated. As a consequence, activated 
Kupffer cells release great amounts of inflammatory mediators resulting in 
malfunction of hepatocytes and Kupffer cells finally ending in cell death. This cell 
deficit contributes to accumulation of endotoxin as well as inflammatory mediators in 
combination with substantial loss of detoxification capacity. Inflammatory mediators 
as components of the innate immune response are normally concerned with host 
defences against infection but can cause cell and tissue damage and hence multiple 
organ failure during the complex clinical syndrome of sepsis. During infection, the 
host produces several proinflammatory cytokines, like IL-6 that have been implicated 
as playing a critical role in pathogenesis.  
During sepsis, mononuclear cells play a key role, releasing the classic pro-
inflammatory cytokines IL-1, IL-6 and TNF. The most consistent correlations of 
clinical severity in inflammatory, autoimmune, or infectious disease with plasma 
cytokine levels are related to IL-6. And also the best correlation of plasma cytokine 
levels with mortality from septic shock has been made with IL-6, demonstrating a 
marker for fatal outcome in patients 118-120. Therapeutic strategies targeting cytokine 
receptors involved in inflammatory signalling have shown promising results in 
experimental models of sepsis 121-124. 
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1.5.  Knockout technology and transgenic mice 
 
Since beginning of the 20th century mice are used in experimental animal 
models due to their high reproduction rate, easy generation and relatively cheap and 
easy breeding. Thus the species of mice became one of the physiologically and 
genetically most intensively studied mammalian. This extensive knowledge of murine 
genetic and physiology established a basis for genetic manipulation of mice like the 
embryonic stem (ES) cell system. Genetic changes introduced into ES cells in tissue 
culture can be transferred into live mice 125-127, breeding the chimeras and screening 
offspring for the ES genotype.  
Although knockout technology in mice is highly advantageous, it can also 
contain limitations. Due to developmental defects, many knockout mice die during 
embryogenesis or shortly after birth. In this case conditional knockout mice provide 
the opportunity of gene deletion on demand, allowing for cell- or tissue-specific gene 
targeting as well as inactivation in a particular stage of development 128.  
The most widely used method to make conditional knockout models is using 
the Cre-loxP recombinase system employing the DNA sequences and enzymes used 
by bacteriophage P1 to excise itself from a host cell’s genome 129-131. As a typical 
recombinase, Cre (“causes recombination”) deletes the DNA fragment located 
between two recognition sites, e.g. the LoxP sites 132. Regulated by definite 
promotors the activation of the Cre recombinase and thus the excision of the 
particular gene is controlled during a specific developmental stage, like in 
hepatocytes (AlfpCre promoter) 133 or when induced exogenous by interferon or pIpC 
(Poly-Inosin-Poly-Cytidilin) injection (Mx promoter) 134.  
 
 
1.5.1. Hepatocyte-specific deletion of gp130 in mice 
 
Gp130 knockout mice die in utero or directly after birth due to myocardial 
hypoplasia and reduced hemopoiesis in the fetal liver 135-137. Therefore, in an earlier 
study of IL-6-gp130-dependent signalling during liver regeneration inducible gp130 
knockout mice using Cre recombinase under the control of the Mx promoter were 
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generated 53. In this approach gp130 could be deleted on demand, although in all 
cells that were sensitive to interferon. Since interferon is produced even during mild 
infections this approach is prone to misinterpretations.  
Thus, for the current study, hepatocyte-specific gp130-deficient mice were 
generated by crossbreeding Cre-transgenic mice under the hepatocyte-specific 
albumin promotor (AlfpCre) and gp130loxP mice, in which LoxP sites flank exon 16, 
encoding the transmembrane domain of gp130 137. Expression of Cre recombinase 
controlled by the hepatocyte-specific albumin promoter results in a more than 90% 
deletion of exon 16 in the adult liver 138. Since nonparenchymal cells show no gp130 
deletion, the overall extent of hepatic gp130 inactivation is likely to reflect complete 
gp130 deletion in hepatocytes. Hence, the albumin promoter was used providing one 
of the most widely known sequences to direct strong transgene expression in the 
liver because of the limited activity uniquely in hepatocytes 133.  
 
 
 
Figure 3: Structure of the AlfpCre transgene. The Cre recombinase was expressed under the 
control of the mouse albumin enhancer and promoter and the three mouse alpha-fetoprotein 
enhancers (filled boxes). To ensure correct polyadenylation of the Cre mRNA, a 2.1 kb fragment of the 
human growth hormone gene 139 has been cloned downstream of the Cre open reading frame (ORF). 
Transgenic mice were generated by injecting FVB/N oocytes (inbred mice strain; commonly used for 
transgenic injection) with the NotI fragment of the Alfp-Cre DNA construct. The depiction was adopted 
from Kellendonk et al. 133. 
 
The hepatocyte-specific Cre transgenic mouse strain has been described 
earlier by Kellendonk et al. 133 and contains a Cre recombinase under control of 
AlfpCre promoter (Figure 3). Including the three mouse AFP enhancers the AlfpCre 
transgene becomes active at day 13,5 p.c. highly efficient and selectively in 
hepatocytes 133. 
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1.5.2. Hepatocyte-specific selective deletion of gp130-STAT 
and -Ras/Erk signalling 
 
Gp130 results in activation of two major pathways (cp. 1.1.2.; 1.1.3.; Figure 1). 
The STAT pathway encompasses the four membrane-distal phospho-tyrosine (pY) 
binding sites for the SH2-domain of the latent transcription factors STAT-1 and 
STAT-3, with STAT-3 having the predominant role in vitro and in vivo 140,141. The 
other pathway comprises the membrane-proximal pY757 (mice) residue in gp130 
responsible for engagement of SHP2 and subsequent activation of the Ras/Erk 
pathway 140,142.  
For selective blockage of these pathways in response to gp130 engagement 
the group of M. Ernst generated two mice strains carrying knock-in mutations as 
previously described 143,144 and depicted in Figure 4. 
 
  
 
 
Figure 4: Generation of gp130 mutant mice 
a) wildtype situation of the gp130 protein  
b) Targeting strategy for the introduction of the gp130∆STAT truncation according to Ernst et al. 145. 
The cytoplasmic domain of mouse gp130 with its homology motifs Box1, Box2, and Box3 (black) are 
schematically depicted alongside the corresponding genomic structure with designated exon 18 
according to Betz et al. 137.  
c) targeting strategy for the introduction of the gp130 Y757 knock-in mutation according to Tebbutt et 
al. 143. 
Wildtype protein 
gp130 ∆STAT protein 
gp130 Y757 protein 
a) 
b) 
c) 
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In order to separately inactivate only one of these two signalling pathways 
selectively in hepatocytes, gp130 mutant animals either deficient for Ras/Erk 
signalling or STAT signalling were combined with tissue-specific gp130 knockout 
animals (AlfpCre gp130LoxP/LoxP) (Figure 5). Thus, gaining heterozygous litter 
providing a monoallelic expression of the pathway specific mutation in any somatic 
cell, in the liver the other conditionally gp130 deleted allele limits downstream 
signalling to at least one of the two pathways.  
 
 
Figure 5: Strategy of generating different hepatocyte-specific gp130-deficient mice.  
a) AlfpCre gp130LoxP/LoxP mice were generated by breeding AlfpCre mice with animals expressing 
LoxP-flanked gp130 alleles 138.  
b) Hepatocyte-specific gp130∆STAT/LoxP animals (AlfpCre gp130∆STAT/LoxP) were generated by 
crossing AlfpCre gp130LoxP/LoxP with gp130∆STAT/∆STAT mice (c), which express a truncated 
gp130 knockin allele encoding a truncated gp130 protein that lacks the domains mediating STAT1 and 
STAT3 activation 137.  
e) Hepatocyte-specific gp130Y757F/LoxP animals (AlfpCre gp130Y757F/LoxP) were bred by crossing 
AlfpCre gp130LoxP/LoxP with gp130Y757F/Y757F mice (d), which express a gp130 allele encoding a 
phenylalanine substitution of the Y757 residue 143, thereby rendering gp130 incapable of recruiting 
SHP2 and activating the RAS-MAPK pathway. Animals were genotyped by PCR analysis for AlfpCre, 
gp130LoxP and gp130Y757F and gp130∆STAT alleles. 
 
a) 
b) 
c) d) 
e) 
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1.6. Aims of the present studies 
 
At present, technical means for a cell-type-specific drug targeting in the liver 
like in most other organs are not available. Currently, the conditional knockout 
technology, is the most promising approach to study gene and protein function in 
defined cell populations in the liver and will provide the knowledge that is needed for 
application of the next generation of molecular drugs that potentially modify survival 
pathways in the liver 146. In the present studies transgenic mice were used to 
investigate signal transduction emanating from the cytokine receptor gp130 in 
hepatocytes during liver regeneration, in liver dependent iron homeostasis regulated 
by hepcidine and in gram-positive sepsis. 
 
1.6.1. The role of hepatocyte-specific selective deletion of gp130-
STAT and -Ras/Erk signalling during liver regeneration 
 
In an earlier study conditional gp130 knockout (MxCre gp130LoxP/LoxP) mice 
were used to study the role of gp130 during liver regeneration (13). These mice had 
a severe phenotype after PH, when they were co-stimulated with lipopolysaccharide 
(LPS) and a high percentage – in contrast to controls – of the animals died and 
showed impaired hepatocyte proliferation. Because the role of gp130 signalling 
during liver regeneration is still controversially discussed 53,105,147 and due to the 
results from MxCre gp130LoxP/LoxP mice 53 two important questions arised. First, it 
should be analyzed, if this phenotype is related to deletion of gp130 in hepatocytes 
and second the contribution of either the Ras/Erk and/or the STAT pathway should 
be clarified in this study. 
Therefore in the present study mice either deficient for hepatocyte-specific 
gp130-dependent Ras/Erk (AlfpCre gp130Y757F/LoxP) or STAT (AlfpCre 
gp130∆STAT/LoxP) activation were used. This strategy allows to specifically address 
and define the role of IL-6/gp130-Ras- or IL-6/gp130-STAT-dependent signalling in 
hepatocytes.  
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1.6.2.  Analysis of the IL-6-gp130-dependent pathway resulting 
in activation of hepcidin 
 
Hepcidin is readily stimulated by LPS 58 or turpentine 63 both in vivo and in 
vitro. This stimulation is indirect and appears to be mainly mediated by the 
inflammatory cytokine IL-6 50. In fact, a neutralizing antibody against IL-6 blocks 
hepcidin induction in vitro and IL-6 knockout mice fail to upregulate hepcidin in 
response to turpentine 148,149. The emergence of hepcidin as the pathogenic factor in 
most systemic iron disorders should provide important opportunities for improving 
their diagnosis and treatment. The use of distinct downstream signalling pathways 
from different phosphorylation sites of the gp130 intracellular domain enables ligand- 
and tissue-specific activation of specific target genes on regulation of hepcidin. For 
these reasons, IL-6 signalling allows a complex plasticity. The aim of this project was 
to identify the IL-6-gp130-dependent pathway that leads to hepcidin activation in 
hepatocytes. 
 
 
1.6.3.  Examination of liver-specific blockage of gp130 in the 
course of experimental gram-positive sepsis 
 
Despite aggressive antibiotic treatment and critical care support, the mortality 
rate of sepsis remains high, probably because the pathogenesis of this syndrome is 
poorly understood 115. In addition, the treatment of septic patients has been further 
complicated by the emergence of antibiotic resistant gram-positive bacteria. 
Therefore, there is a clear need to develop more effective treatments for sepsis 
based on the identification of novel targets. The development of these new 
therapeutic approaches is not an easy task due to the complexity of the 
immunological defences and the feed-back mechanisms of the different components 
of the inflammatory cascade. A number of adjuvant therapies, aimed at 
blunting/down regulating the host hyper inflammatory response, are currently under 
investigation. Although strategies aimed to down-regulate pro-inflammatory cytokines 
by using antibodies directed against these molecules have proved to be uniformly 
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disappointing 150, strategies targeting receptors involved in inflammatory signalling 
have shown promising results in experimental models of sepsis. Interfering with 
gp130 signalling by using recombinant soluble gp130 protein has already proven to 
be very effective for therapy of inflammatory disorders in mouse models of human 
diseases such as Crohn's disease 151, rheumatoid arthritis 152, and colon cancer 153, 
suggesting that targeting of gp130 may be a promising therapeutic candidate for the 
treatment of sepsis. However, whole-body inactivation of molecules, which are 
pivotal to innate immunity can also have harmful effects. These potential detrimental 
effects can be overcome by targeting these molecules in an organ-specific manner. 
The liver plays a crucial role in the pathogenesis of bacterial sepsis as a source and 
target of inflammatory mediators. Therefore the aim of this study was to examine the 
effect during liver-specific blockage of the gp130 signalling cascade on the course of 
experimental gram-positive sepsis. 
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2.  Material and Methods 
 
 
2.1.  Chemicals 
 
Name of the product        Company 
 
Ammoniumpersulfate (APS)      AppliChem 
Acetone          J.T.Baker 
Agarose          Invitrogen 
Acetic acid (glacial) 100%       AppliChem 
Ammoniumacetate         AppliChem 
Bromophenol Blue         Serva 
BSA (Bovine Serum Albumin)       Sigma 
Calciumchloride (CaCl2)       Sigma 
Chloroform         Merck 
Cetyltrimethylammonium chloride      Sigma 
Collagen Type I from rat tail      Sigma 
Diethyl pyrocarbonate (DEPC)      Sigma  
Diethylether         J.T.Baker 
DTT (Dithiotreitol)         Sigma 
EDTA (N,N;N’,N’-Ethylendiamine-tetraacetate)        Calbiochem 
EGTA (Ethylen glycol-bis (2-aminoethyl)- N,N;N’,N’- tetraacetate) Fluka 
Entellan          J.T.Baker 
Eosine          Sigma 
Ethanol, denaturated 100 %       J.T.Baker 
Ethidiumbromide (EtBr) (Stock 10 mg/ml)     Sigma 
Formamide         AppliChem 
Formaldehyde 37%        Roth 
Glucose          Merck 
Glutaraldehyde        AppliChem 
Glycerol (plant)         Serva 
Glycine         AppliChem 
Hämosin          Merck 
Hydrochloric acid (HCl)        AppliChem 
HEPES (2-[4-2-hydroxyethyl-1-piperazinyl]-ethansulfon acid)  Merck 
Sulfuric acid (H2SO4)       Merck 
Lipopolysaccharide (LPS; E.coli O55:B5)     Sigma  
Magnesium chloride (MgCl2)      Sigma 
Milk powder  (nonfat)       Merck 
β-Mercaptoethanol         AppliChem 
Methanol         J.T.Baker 
MOPS (3-[N-Morpholino] propanesulfonic acid)   Sigma 
Nonidet P – 40         Sigma 
Paraformaldehyde         Merck  
PBS (Phosphate buffered saline)      Biochrom  
Phenylmethyl sulfonyl fluoride (PMSF)     Roth 
Ponceau Red        Sigma 
Potassium chloride (KCl)       Merck 
2   MATERIAL AND METHODS 
 
 
 
23
2-Propanol          Merck 
Salicylic acid         Sigma 
Sodium carbonate (Na2CO3)      Merck 
Sodium hydrogencarbonate (NaHCO3)     Merck 
Tri-sodium citrate 2-hydrate      Roth 
SDS (Dodecylsulfate)       Roth 
Sodium fluoride (NaF)       Roth 
di-sodiumhydrogenphosphate 2-hydrate (NaH2PO4)   Roth 
Sodium vanadate (Na3VO4)      Sigma 
TEMED (N,N,N’,N’-Tetramethylethylendiamine)    Sigma 
3,3-5,5-tetramethyl-benzidine      Sigma 
Tris-(hydroxymethyl)-propane-1,3-diol     AppliChem 
Triacetic acid         Merck 
Triton X-100          Sigma 
Trypan blue stain 0,4%       Gibco 
TWEEN-20          Sigma 
Xylene         J.T.Baker 
 
 
2.1.1.  Radiochemicals 
 
[32P]-γ-ATP (10mCi/ml)       Hartmann Analytic 
[32P]- α-CTP (10mCi/ml)       Hartmann Analytic 
[3H]-Thymidine (10mCi/ml)      Hartmann Analytic 
 
 
2.2.   Instruments and equipment 
 
Botting Trans-BlotTM Cell        BioRad 
Cell culture centrifuge Megafuge 1.0R     Heraeus 
Cell culture flow        Gelaire 
Cell culture Incubator       Heraeus 
Centrifuge 5415D        Eppendorf 
Cooling centrifuge 5417R       Eppendorf 
Cryostat HM 550        Microm 
ELISA Reader µQuant       BIO-TEK 
+KC4 Software 
Gel dryer         Biometra 
Liquid scintillation counter 1219 Rack Beta    LKB Wallac 
Overhead shaker REAX 2       Heidolph 
Perfusion pump        Ismatec 
pH Meter PB-11        Sartorius 
Powersupply PowerPac HC      BioRad 
7300 Real Time PCR System              Applied  
+ Sequence Detection Software Version 1.3.1.    Biosystems 
Roller Mixer SRT 9        Stuart 
Rotating incubator        Bachofer 
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SDS PAGE electrophoresis system PerfectBlue Twin L  Peqlab 
   
Shaking incubator Unimax 1010       Heidolph 
Thermocycler T3000 and Tpersonal      Biometra 
Thermomixer 5436         Eppendorf 
UV Stratalinker         Stratagene 
Water bath Haake W13        Fisons 
Weighing maschines        Sartorius 
    
 
2.3.  Consumables  
 
2.3.1.   General material 
 
Hybond N membranes         Amersham 
Nitrocellulose membrane Protran ®      Whatman 
Scintillation tubes Pony vialTM       Packard 
Scintillation fluid Ultima GoldTM XR      Packard 
Super Frost slides         Roth 
X ray films           Amersham 
 
 
2.3.2.  Material for animal experiments  
 
Name of the product        Company 
 
Catheter with injection port (Biovalve® 20G; 1,0x32mm)   Vygon 
Disposable Scalpels sterile No. 10, 11, 21     Feather 
Ethibond® Excel plated, laminatet, not absorbable; 6/0 metric 0,7  Ethicon 
General chow for rodents         Altromin 
Hematocrit capillary         Brand 
Heparine (Liquemin®)        Roche 
Injection needles (Sterican®; Gr.17 24Gx25mm; 0,4x12mm)   Braun 
Isoflurane (Forene®)        Abbott 
Ketamine (Ketamin®)        Albrecht 
Micro tube (1,1 ml Z-Gel)        Sarstedt 
Sterile gossamer (Sterilkompresse®)      Beese 
Surgical instruments        Aesculap 
Syringe Omnican®         Braun 
Vicryl®, absorbable 4-0        Ethicon 
Xylazin (Rompun®)         Bayer 
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2.3.3.  Material of cell- and bacterial culture 
 
Cell scrapers         Costar 
Cell culture plates (6 well)        Costar 
DMEM  +4500mg/L Glucose      Invitrogen 
  +GlutaMAX 
  +Pyruvate 
 
Fetal Calf Serum (FCS)        PAA  
Hepatozyme®          Invitrogen 
10x PBS pH 7,4         Gibco 
Penicillin/Streptomycin (P/S)       Gibco 
 
Todd-Hewitt broth          Oxoid  
Blood agar plates         Gibco 
 
2.4.  Antibodies 
 
Primary Antibodies: 
 
anti-Cdk2      (M2; sc-163; Santa Cruz) 
anti-cyclin A       (clone C19; sc-596; Santa Cruz) 
anti-cyclin D1     (72-13G; sc-450; Santa Cruz) 
anti-GAPDH       (Biogenesis 4699-9555) 
anti-p-p44/42 (Erk1/2) Map Kinase   (T202/Y204; #9106s; Cell Signaling) 
anti-p-STAT-3      (Tyr705; #9131s; Cell Signaling)  
 
Secondary antibodies:  
 
HRP-linked anti-mouse immunoglobulin G  (sc-2005; Santa Cruz)  
HRP-linked anti-rabbit immunoglobulin G  (#7074; Cell Signaling) 
 
 
2.5.  Enzymes 
 
DNA Advantage® 2  Polymerase Mix (2,5U/µl)     Clontech 
DNAse I Amp Grade (40U/µl) (+ 10x DNase Reaction Buffer)  Invitrogen 
DNA Taq Polymerase (5U/µl) (+10x PCR-MgCl2 buffer)   Invitrogen 
Liberase Blendzyme®        Roche 
M-MLV (200U/µl)         Invitrogen 
Myeloperoxidase (human; purified)      Sigma 
Proteinase K          AppliChem 
SYBR® GreenER qPCR SuperMix      Invitrogen 
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2.6.  Analytical chemicals, reagents and kits 
 
Product          Company 
 
30% Acrylamide/Bis Solution, 37,5:1 (2,6%C)    Biorad 
ATP (Adenosintriphospate; 10mM; for Kinase Assay)   Invitrogen 
Biorad reagent®         Biorad 
Cell Proliferation (BrdU) Kit®BrdU     GE Healthcare 
Complete Mini® (Proteinase Inhibitor Cocktail)    Roche 
Coomassie-Brilliant-Blue®       Roth 
Covering solution for cryo sections (Tissue-Tek®)    Sakura 
Diaminobenzidine (DAB)        Sigma 
DNA marker 1kbplus Ladder®       Invitrogen 
DNA Taq Polymerase (5U/µl)       Invitrogen 
ECL-Western-Blot-analysis®       GE Healthcare 
EDTA (25mM)        Invitrogen 
Histone H1 recombinant (5µg/ml)     Upstate 
Mayer's hematoxylin solution       Merck 
MgCl2 (50mM; for PCR)        Invitrogen 
Mounting Medium®         Vector  
Protein HighRange Rainbow Molecular Weight marker®  Amersham  
Tetramethylbenzidine substrate (TMB)     Sigma 
pcDNA3.1/V5/His-TOPO       Invitrogen 
peqGOLD-RNAPure®       Peqlab 
Protein A agarose beads        Roche 
Random Primers (3µg/µl)       Invitrogen 
Random priming kit (High Prime Kit)      Roche 
RNase OUT® Ribonuclease Inhibitor (40U/µl)    Invitrogen 
 
2.6.1.  ELISA Kits 
mouse IL-6         R&D Systems 
mouse KC          R&D Systems 
OptEIA TM mouse IL-10 Elisa Kit      BD Bioscience 
OptEIA TM mouse IFN-γ Elisa Kit      BD Bioscience 
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2.7.  Animal experimental methods 
 
2.7.1. Animal breeding  
 
Animals were bred under standardized conditions following National Academy 
of Sciences (NIH publication 86-23 revised 1985) criteria in the animal research 
institute of the Medizinische Hochschule Hannover (MHH) until oktober of 2005 and 
thereafter transferred to the “Institut für Versuchstierkunde” of the University Hospital 
of the RWTH Aachen (UK Aachen). During breeding and the subsequent 
experiments a 12 hours light-dark rhythm, standardized temperature of 20-24°C and 
humidity of 50-60% was maintained by central air conditioning. Mice were housed in 
macrolon cages providing food and water ad libitum and were grouped up to 10 
animals per cage. Biopsies of tail tips for genotyping were taken after earmarking and 
separation of the litter mates from the breeding couples. All studies were approved 
by the appropriate authorities according to the german legal requirements.  
 
2.7.2. Generation of gp130-mutated animals 
 
2.7.2.1. AlfpCre gp130LoxP/LoxP  
Conditional hepatocyte-specific gp130 knockout mice were generated by 
mating AlfpCre mice with mice expressing LoxP-flanked gp130 alleles. Gp130 
LoxP/LoxP mice lacking the Cre transgene were used as control (wildtype) animals.  
 
2.7.2.2. AlfpCre gp130∆STAT/LoxP  
Hepatocyte-specific gp130∆STAT/LoxP animals were generated by breeding 
conditional AlfpCre gp130 LoxP/LoxP with gp130∆STAT/∆STAT knockin mice. 
Gp130∆STAT/∆STAT expresses a truncated gp130 knockin allele that lacks the 
essential region for activation of STAT1 and -3 signalling.  
 
2.7.2.3. AlfpCre gp130Y757F/LoxP 
Hepatocyte-specific gp130Y757F/LoxP animals were generated by crossing 
conditional AlfpCre gp130LoxP/LoxP with gp130Y757F/Y757F knockin mice. The 
gp130Y757F/Y757F mice express a gp130 allele with a point mutation at Y757. 
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2.7.3. In vivo stimulation of transgenic mice 
 
For in vivo IL-6 stimulation controls and gp130-modified mice received a single 
i.p. injection of 250µg/kg recombinant IL-6. Recombinant IL-6 was produced and 
provided by P. Heinrich (Aachen, Germany) and S. Rose-John (Kiel, Germany). 
  
2.7.4. Partial (2/3) Hepatectomy  
 
Partial hepatectomy (PH) was performed according to the protocol of Higgins 
and Anderson 154. Pathogen-free 8- to 10-week old male mice were anaesthetized by 
intraperitoneal application of Ketamin/Xylazin considering the body weight (100mg/kg 
Ketamin combined with 10mg/kg Xylazin). A midline laparotomy was done, the 
incision extending from the right border of the sternum, along the xiphoid, with care to 
avoid accidental penetration into the chest cavity. The four major lobes were 
identified (right, median, left, and caudate); the two segments of the median lobe 
(lateral and medial) were noted to be partially divided by the gallbladder. 
Subsequently, the right, left and the lateral portion of the median lobe were ligated 
with a silk tie (Ethibond® Excel). The ligated tissue was resected, whereas damage of 
the gallbladder, the extrahepatic biliary tree, the abdominal aorta, and the portal vein 
needs to be prevented (Figure 6). After resection of the liver lobes the peritoneum 
and the dermis were closed separately and postoperative care was taken.  
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Figure 6: Drawing of the mouse liver shows four lobes with relative percentages. The gall 
bladder (Gb) fossa is dividing the lateral and medial segments of the median lobe. The liver lobes 
resected during PH are marked in grey and form approximately 68% of the total volume of the organ. 
According to Higgins and Anderson, during partial hepatectomy the left, right and the lateral part of the 
median lobe is removed. (Drawing was adapted from R.J. Doerr et al. 155) 
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2.7.5. Isolation of primary Hepatocytes 
 
Cells taken directly from the living organism known as primary cell culture can 
keep the differentiated state for a short period (days to weeks). In contrast to cultures 
of immortalized cells these cells can keep their cellular function, which they fulfill in 
the entire organ. Hence they provide a physiological situation. In the present projects 
primary mouse hepatocytes from transgenic mice were isolated by collagenase 
perfusion. Mouse livers were perfused with a Krebs Ringer buffer in retrograde 
fashion followed by perfusion with a collagenase solution. 
Therefore mice were i.p. sedated and anaesthetized with Ketamin/Xylazin 
depending on the body weight (100mg/kg Ketamin combined with 10mg/kg Xylazin) 
and anticoagulated with 50µl of low molecular heparine (Lequemin®). After fixation of 
the sedated animal in dorsal position the abdominal cavity was opened with a 
caudocranial cut in the Linea alba. Subsequently the Vena portae is laid open and an 
intravenous catheter (Biovalve® 20G) was applicated. After opening the Vena cava 
caudalis perfusion with a buffer including EDTA (Solution A) was performed with a 
flow rate of 2ml/min until the hepatic vascular system was clarified from blood. 
Immediately the perfusion was continued with a buffer containing Liberase 
(Blendzyme 3®) and CaCl2 (Solution B). As soon as the structure of liver tissue 
seemed to be abrogated, perfusion was stopped and the organ was withdrawn. 
Accordingly, the following procedure was carried out under sterile conditions. The 
capsule of the liver was opened in ice cold DMEM medium for release of the 
separated hepatocytes.  
The suspension was then filtered through sterile gossamer (Sterilkompresse®) 
and centrifuged at 300xg at 4°C for 2 minutes to separate viable cells from tissue and 
cell residues. After discarding the supernatant the pellet was taken up in fresh 
medium for another washing procedure. Finally cells were resuspended in 
Hepatozyme® medium containing 10% fetal calf serum (FCS), penicillin and 
streptomycin. Viability of hepatocytes was determined using a Neubauer counting 
chamber and were subsequently disseminated with a density of 8x105 cells per 6 cm 
well. The day before, plates were prepared and wells were coated with collagen. 
Adhesion and survival of cells was controlled after three hours and cells were 
washed intensely with sterile 1x PBS (3ml per well). Following, primary hepatocytes 
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were cultured under serum-free conditions overnight at 37°C and 5% CO2. The next 
day cells were applied to experiments and stimulation. 
 
Solution A:     Solution B:     
9 g/L  NaCl    Solution A without EDTA, 
0,42 g/L KCl    (sterile filtrated, adjusted to pH 7,4) 
0,99 g/L Glucose     
4,8 g/L HEPES    freshly added:  
2,1 g/L NaHCO3    and 10 mg Liberase 
sterile filtrated, adjusted to pH 7,4  and 0,5M CaCl2 
 
freshly added: 1mM EDTA 
 
 
2.7.5.1. Stimulation of primary hepatocytes 
 
 
Stimulation of 8x105 cells per 6cm well was performed with 200ng/ml 
recombinant IL-6 and/or 50ng/ml recombinant HGF. Recombinant IL-6 was produced 
and provided by P. Heinrich (Aachen, Germany) and S. Rose-John (Kiel, Germany). 
Recombinant HGF was kindly provided by E. Gherardi (Cambridge, UK). 
 
 
2   MATERIAL AND METHODS 
 
 
 
32
2.7.6. Streptococcus pyogenes infection model  
 
 
2.7.6.1. Bacteria 
 
The Streptococcus pyogenes A20 strain is a human isolate obtained from the 
German Culture Collection (DSM 2071). Stock cultures were maintained at -70°C 
and were routinely cultured at 37°C in Todd-Hewitt broth, supplemented with 1% 
yeast extract for approximately 6 hours. Bacteria were collected in mid-log-phase, 
washed twice with sterile PBS, diluted to the required inoculum and the number of 
viable bacteria determined by counting colony forming units (CFU) after diluting and 
plating in blood agar plates containing 5% sheep blood.  
 
2.7.6.2. Infection and determination of bacterial loads  
 
Female FVB/n AlfpCre gp130LoxP/LoxP mice and gp130LoxP/LoxP control 
mice between 8 and 10 weeks of age were inoculated with 105 CFU of S. pyogenes 
in 0,2 ml of PBS via a lateral tail vein. For kinetic studies the infected mice were 
sacrificed by CO2 asphyxiation and bacteria from the liver and spleen were 
enumerated, by preparing homogenates of these organs in PBS. Additionally blood 
was taken from the tail vein at different times post-inoculation. 
Serial dilutions (10-fold) of tissue homogenates and blood samples were plated on 
blood agar and colonies were counted and evaluated after 24 hours incubation at 
37°C.  
The infection procedure was performed in cooperation with the Infection 
immunology research group, Division of Microbiology, Department of Microbial 
Pathogenesis and Vaccine Research, HZI-Helmholtz Centre for Infection Research, 
Braunschweig, Germany. 
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2.8.  Isolation and analysis of nucleic acids 
 
2.8.1. Extraction and purification of DNA 
 
2.8.1.1. Isolation of genomic DNA from tail biopsies 
 
To genotype mice by PCR, DNA was isolated from murine tail tips of around 
0,5 cm in length. The tissue was lysed for at least 1 hour at 55°C in 500µl of lysis 
buffer containing 25µl of proteinase K (15,6mg/ml, Roche). The samples were 
centrifuged for 5 minutes at 14000 rpm. 500µl of 2-propanol were added to the 
achieved supernatant for precipitation. After mixing thoroughly centrifugation was 
performed for another 5 minutes. Supernatant was discarded and the nucleic acid 
containing pellet was washed twice in 70% ethanol for removal of salts by mixing and 
subsequent centrifugation at 14000rpm for 2 minutes. The pellet was dried at 37°C 
and resuspended in 200 µl 1M RNAse/TE. Storage was carried out at 4°C. 
 
Lysis buffer:       RNAse TE: 
50 mM Tris-HCl pH 8     10 mg RNAse 
100 mM EDTA pH 8     100 ml 1xTE, pH 8 
100 mM NaCl 
1 % 20 % SDS 
0,5 mg/ml Proteinase K (added freshly)  
 
 
2.8.1.2. Isolation of genomic DNA from liver tissue  
 
DNA isolation from mouse liver tissue was performed by cutting a small peace 
of deeply frozen tissue (size of around 2mm3). Lysis and isolation was performed as 
described above.  
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2.8.1.3. Determination of DNA concentration 
 
For determination of DNA concentration a sample was diluted 1:20 and optical 
density was measured at 260nm. Calculation of concentration based on the formular: 
1OD260 = 50 µg DNA/ml. The purity of DNA was analyzed with additional 
determination of the extinction at 280nm. A ratio of E260/E280 between 1,7 and 1,9 
accounts for pure DNA. 
 
 
2.8.2. Extraction and characterization of RNA 
 
2.8.2.1. Isolation of RNA from liver tissue 
 
From deep frozen liver tissue around 50mg was cut off on dry ice and 2 ml of 
peqGOLD-RNAPure® was added. After homogenization with a potter the lysate was 
incubated for 5 minutes at room temperature. After adding 400µl of chloroform under 
an extractor hood the sample was vortexed thoroughly for 15 seconds and again 
incubated at room temperature for 10 minutes. Due to centrifugation at 13000 x g for 
5 minutes the lysate formed up three phases. The liquid upper phase beared the 
disassociated RNA, whereas the interphase and the lower phase contain impurities 
of DNA and protein. Avoiding any contact with the interphase, the upper phase was 
transferred carefully to a fresh reaction tube. After addition of 500µl 2-propanol 
samples were incubated for 10 minutes at room temperature. Precipitated RNA was 
then isolated by centrifugation for 10 minutes at 13000 x g and 4°C. After discarding 
the supernatant the pellet was washed twice with 1 ml 70% ethanol. For washing, 
centrifugation was performed at 13000 x g at 4°C for 10 minutes. Subsequently the 
pellet was dried for 5 minutes and in dependence of the dimension dissolved in 40-80 
µl RNAse-free dH2O by incubation at 60°C. Storage of isolated RNA was performed 
at -80°C. 
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2.8.2.2. Isolation of RNA from cell culture 
 
Plated primary hepatocytes were washed twice with 3 ml of sterile 1x PBS 
after removal of cell culture medium. Then 2 ml peqGOLD-RNA Pure® was pipetted 
in each well of the commonly used 6-well-plate and scraping was performed using 
cell scrapers. Cell lysates were transferred to reaction tubes and treated like samples 
gained from liver tissue. 
 
2.8.2.3. Determination of RNA concentration 
 
Purified RNA was diluted 1:50 in RNAse-free dH2O to measure optical density 
at 260nm (OD260). Adjustment was done measuring dH2O. Calculation based on the 
formular: 1OD260 = 40 µg RNA/ml. The purity of RNA was analyzed with additional 
determination of the extinction at 280nm. The ratio of E260/E280 between 1,9 and 2,1 
accounts for pure RNA. 
 
2.8.2.4. Purification of RNA by DNase I digestion 
 
RNA used for RT-PCR should be completely free of genomic DNA 
contamination. The presence of genomic DNA can generate false positive products 
amplified during PCR. The most effective method of removing DNA from RNA 
preparations is to digest with DNase I. Therefore, prior to RT-PCR the RNA sample is 
treated by RNAse free DNAse using the following ingredients (Invitrogen):  
 
Reaction Mix: 
3µg  RNA sample diluted in 5µl of DEPC-treated H2O 
1 µl  10x DNase Reaction Buffer  
1 µl  DNAse I Amp Grade (40U/µl) 
2,5 µl  DEPC- H2O 
 
The reaction mix was incubated for 10 min at 65 °C. After that for inactivation of the 
enzyme 1,5µl of 25mM EDTA was added and incubated at 95°C for 1 minute. 
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 2.8.2.5. RNA gel electrophoresis 
 
Twenty micrograms of total RNA extracts were run in a 1,2% agarose/1x 
MOPS/0,22M formaldehyde gel in 1x MOPS/0,22M formaldehyde running buffer at 
100–150 Volt. Therefore samples were prepared with 5x loading dye and incubated 
at 65°C for 5 minutes. 
 
 
10x MOPS-Puffer pH 7, add 1000ml:    5x Loading Dye, add 10ml: 
41,8g MOPS (0,2M)      16µl bromophenol blue solution 
6,8g sodium acetate (50mM)     80µl 0,5 M EDTA, pH 8 
2 ml 0,5 M EDTA, pH 8 (0,01M)     100 µl EtBr (Stock 10 mg/ml) 
720 µl 37% formaldehyde 
2 ml glycerol 
3084 µl formamide 
4 ml 10x MOPS 
 
2.8.2.6.  Northern Blot Analysis  
 
Northern blot analysis was performed according to standard procedures 156. 
Twenty micrograms of total RNA extracts were run in a 1,2 % agarose formaldehyde 
gel. Separated RNA samples were transferred to a Hybond N membrane according 
to the SSC semidry blot method and were subsequently crosslinked.  
cDNA probes were labeled with α32P-dCTP using a random priming kit 
(Roche). For quantification, blots were exposed for autoradiography and to an image 
plate. The counts of signals were distributed according to counts of the 18S/28S 
signal and were normalized to untreated animals. 
 
The hepcidin cDNA probe (317bp) was generated by PCR from hepatic mouse RNA 
with the following primers:  
forward, 5’-ACC ATG GCA CTC AGC ACT CG- 3’  
and reverse, 5’ –GCG GCT CTA GGC TAT GTT TT- G3’ 
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and cloned in the vector pcDNA3.1/V5/His-TOPO according to standard protocols 
provided by the manufacturer. 
Hybridization was performed at 42°C with random-primed α32P-dCTP labelled 
cDNA probes for hepcidin and β-actin. 
 
SSC buffer, pH 7,0:  3M NaCl; 0,3M sodium citrate-2-hydrate   
 
2.8.3. Polymerase chain reaction (PCR) 
Since the original protocol for the polymerase chain reaction (PCR) was 
established in 1985 157 the procedure was subjected to continuous enhancement up 
to analyzing of the PCR product in real-time.  
 
2.8.3.1. Genotyping of gp130-transgenic mice using PCR 
 
Individual mice genetically modified at the gp130 locus or transgenic for the 
cre recombinase were genotyped using a PCR approach according to the following 
protocols: 
 
Oligonucleotides used in PCR diagnosis of the transgenic mice strains:  
 
AlfpCre gp130 LoxP/LoxP,  
AlfpCre gp130Y757F/LoxP,  
AlfpCre gp130∆STAT/LoxP: 
 
Sequences of primers (MWG Biotech) are listed in 5‘-3‘-orientation: 
 
Target gene Name                                                                                           Sequence
Cre sense CCA CGA CCA AGT GAC AGC AAT Cre transgene 
Cre antisense TTC GGA TCA TCA GCT ACA CCA 
gp130 loxP sense GGC TTT TCC TCT GGT TCT TG gp130 flanked  
LoxP sites gp130 Lox P antisense CAG GAA CAT TAG GCC AGA TG 
∆ wildtype CAA GTG TCC TCA AGG TCC GAG TCC AC  
∆ mutant CTG AAT GAA CTG CAG GAC GA 
Deletion of  
STAT- or Ras/Erk  
signalling ∆ common TGA AGC CAC TCG TCT TTA GC 
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Reaction Mix :   
2 µl   10x PCR-MgCl2 buffer   (Invitrogen)                
0,25 µl  Sense Primer (100 µM)        
0,25 µl  Antisense Primer (100 µM)    
0,6 µl  50mM MgCl2 (Invitrogen)    
1,6 µl   2,5 mM dNTP Mix (Invitrogen)    
2 µl   DNA template  
0,2 µl   DNA Taq Polymerase (5U/µl) (Invitrogen)    
13,1 µl    dest. H20_______________  
20 µl   final volume   
 
PCR´s for the Cre transgene and the LoxP insertions were carried out according to 
the following program: 
 
Procedure   Temperature  Duration   Step               Cycle 
1. Denaturation  95°C    3 minutes 
2. Denaturation  95°C    15 seconds 
3. Annealing Tm  54°C    30 seconds 
4. Elongation  72°C    30 seconds   2.      35 
5. Elongation  72°C    2 minutes 
6. Conservation 4°C    ∞ 
 
Reaction Mix :   
2 µl   10x PCR-MgCl2 buffer        
0,25 µl  Sense Primer (100 µM)        
0,25 µl  Antisense Primer (100 µM)    
0,6 µl  50mM MgCl2     
1,6 µl   2,5 mM dNTP Mix    
2 µl   DNA template  
0,2 µl   DNA Taq Polymerase (5U/µl)    
13,1 µl    dest. H20__________________________                                                     
20 µl   final volume 
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Knockin mutations of the gp130 receptor (gp130∆STAT/LoxP and gp130 
Y757F/LoxP) were detected using the Advantage® 2 Polymerase Mix: 
 
Reaction Mix :   
2 µl   10x Advantage® 2 PCR buffer        
0,8 µl   ∆ common  (100 µM)      
0,8 µl   ∆ wildtype  (100 µM)  
0,8 µl   ∆ mutant  (100 µM)      
1,6 µl   2,5 mM dNTP Mix    
2 µl   DNA template  
0,4 µl   DNA Advantage® 2  Polymerase Mix (2,5U/µl)    
11,6 µl    dest. H20_______________  
20 µl   final volume 
 
PCR for detecting the genotype resulting in gp130-defective STAT- or Ras/Erk 
signalling is performed using the following thermocycling program: 
 
Procedure   Temperature  Duration   Step               Cycle 
1. Denaturation  95°C    5 minutes 
2. Denaturation  95°C    30 seconds 
3. Annealing Tm  65°C    30 seconds 
4. Elongation  68°C    1 minutes   2.      31 
6. Conservation 4°C    ∞ 
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2.8.3.2. Reverse Transcription (RT-PCR) 
 
Reverse transcription is a process in which single-stranded RNA is reverse 
transcribed into complementary DNA (cDNA). In combination with real time PCR this 
method is applied for profiling the expression of particular genes. The reaction is 
carried out using total cellular RNA, a reverse transcriptase enzyme, random primers, 
dNTPs and an RNase inhibitor. The resulting cDNA can be used for real time PCR 
analysis.  
For a RT reaction, 3 µg of RNA treated with RNAse free DNAse (cp. 2.7.2.4.) 
was first incubated at 70°C to denature RNA secondary structure and was then 
quickly chilled on ice. Afterwards 38 µl of the reaction mix was applicated to each 
sample. RT reaction was then extended at 37°C for one hour. Finally, the enzyme 
was inactivated by incubation at 95°C for 5 minutes. All reagents were purchased 
from Invitrogen. 
 
Reaction Mix: 
 
10µl   5x First Strand buffer  
2µl   DTT (0,1 M) 
3µl   Random Primer (1:10) 
5µl   dNTP Mix (1:10 dilution of dATP, dCTP, dGTP and dTTP) 
1,25µl  RNase Out (Ribonuclease Inhibitor (40U/µl) 
15µl   DEPC-H2O 
1,75µl  M-MLV (200U/µl) 
 
2.8.3.3. Quantitative real-time PCR (qRT-PCR) 
 
Real-Time PCR provides the opportunity of DNA amplification combined with 
analysis and quantification of the PCR product. Addition of a fluorescent dye like 
SYBR Green I enabled monitoring of PCR reactions in real time. This dye 
intercalates into double-stranded (ds-) DNA and produces a fluorescent signal, 
whose intensity is proportional to the amount of dsDNA present in the reaction. Since 
DNA amplification during PCR appears to be logarithmic, at each step of the PCR 
reaction, the signal intensity increases as the amount of product increases.  
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Especially in gene expression analysis quantitative Real-time PCR is playing a 
decisive role. In order to measure gene expression by quantifying messenger RNA 
(mRNA) reverse transcriptase is needed to convert mRNA into complementary DNA 
(cDNA), which then can be amplified and analyzed by PCR (s. 2.8.3.2.). 
There are several methods to quantify alterations in mRNA levels using real 
time PCR. Absolute quantification, calculating the amount of DNA molecules is 
performed by calibration with a standard curve. In the present studies an 
approximation method was used providing relative quantification. The ∆∆Ct Method 
was one of the first methods to be used to calculate real time PCR results (Applied 
Biosystems; User Bulletin #2: Relative Quantitation of Gene Expression (PN 
4303859). This comparative method involves comparing the Ct values (threshold 
cycle), the fractional cycle number at which the fluorescence passes the fixed 
threshold. The Ct values of samples of interest are compared with a control or 
calibrator such as a non-treated sample or RNA from normal tissue. The Ct values of 
both the calibrator and the samples of interest are normalized to an appropriate 
endogenous housekeeping gene.  
 
 [delta][delta]Ct = [delta]Ct,sample - [delta]Ct,reference 
 
Here, [delta]CT,sample is the Ct value for any sample normalized to the endogenous 
housekeeping gene and [delta]Ct,reference is the Ct value for the calibrator also 
normalized to the endogenous housekeeping gene. 
  
Reaction Mix: 
 
12,5 µl  SYBR® GreenER qPCR SuperMix 
8 µl     DEPC-H20 
1 µl  sense primer (100µM) 
1 µl  antisense primer(100µM) 
2,5µl   cDNA template__________________  
25 µl   final volume 
 
The following PCR programm was used for all real-time primer pairs: 
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Procedure   Temperature  Duration   Step               Cycle 
1. Activation  50°C   2 minutes 
2. Denaturation  95°C    10 minutes 
3. Denaturation  98°C    15 seconds 
4. Annealing Tm* 58°C    30 seconds 
5. Elongation  60°C    30 seconds   3.      40 
6. Conservation 4°C    ∞ 
* Data collection  
The specificity of PCR products was confirmed by melting curves and 
electrophoresis. 
 
2.8.3.4. Oligonucleotides used in quantitative real-time PCR 
 
The following oligonucleotides were used for quantitative real-time PCR 
analysis. Sequences are listed in 5‘-3‘-orientation: 
Target gene Name                                                                                           Sequence
Cyclin E1 sense CTG AAG CAG CCA CAT CCA G Cyclin E1 
Cyclin E1 antisense ACA GCA GGT CTT CGT GCA GAT C 
Cyclin E2 sense CAT AAT GCC TCC ATT ACA CAC TGG Cyclin E2 
Cyclin E2 antisense CCA TGG AAG ATA GAC ACA ATA TCC 
Cyclin A sense CAA CAG TAA ATC AGT TCC TTA CC Cyclin A 
Cyclin A antisense CAT CTA TCA AAC TCA GTT CTC C 
SOCS3 sense CCC GCG GGC ACC TTT CTT AT SOCS3 
SOCS3 antisense CAC TGG ATG CTG AGG TTC TTG GTC 
SAA sense TCT CTG GGG CAA CAT AGT ATA CCT CTC AT SAA 
SAA antisense TTT ATT ACC CTC TCC TCC TCA AGC AGT TAC 
OSM sense CTG ACC TGA GAG CTG CCT G OSM 
OSM antisense CAG GAA GTG AGG CTT GCT CAG 
LIF sense CAC GGC AAC CTC CTG AAC CAG LIF 
LIF antisense CAA CGT TGT TGG GAA ACG GC 
CT-1 sense CTC TAT GGC GAG TGG GTG AGC CT-1 
CT-1 antisense GGC GAG ACA GAG CGA GCT TAC 
Hamp 1 sense CAA CAG ATG AGA CAG ACT ACA GAG CTG CA Hamp 1 
Hamp 1 antisense TAG GCT ATG TTT TGC AAC AGA TAC CAC ACT G 
GAPDH sense AAC CTG CCA AGT ATG ATG ACA TCA GAPDH 
GAPDH antisense TGT TGA AGT CAC AGG AGA CAA CCT  
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2.9.  Isolation and characterization of proteins 
 
2.9.1.  Extraction and quantification of proteins 
 
2.9.1.1. Protein extraction from liver tissue and primary hepatocytes 
 
Frozen liver tissue (~ 0,1 g) was homogenized on ice in 1 ml extraction buffer 
with a glass potter avoiding vigorous shear forces. Primary hepatocytes from cell 
culture were washed twice in PBS and 0,5 ml of extraction buffer was added to each 
well of a 6-well plate. Scraping of the cells leads to homogenization of the cells. 
For purification homogenates of both tissue and cell culture were centrifuged at 
10.000 rpm for 10 minutes at 4°C. Protein concentration of the withdrawn 
supernatant was then determined by Bradford assay (s. 2.9.1.2.) and sample buffer 
was added subsequently. For denaturation samples were heated up to 95°C for 5 
minutes, were loaded to a polyacrylamide gel or were snap-frozen in liquid nitrogen 
and stored at -80°C. 
 
1x Extraction buffer:     2x Sample buffer: 
1M NaCl      500mM Tris pH 6,8 
10mM EGTA      60% Glycerol 
500mM EDTA pH8     25% SDS 
1M NaH2PO4     1% bromophenol blue 
1M Tris pH 7,5     200mM DTT 
1M NaF 
1% Triton X-100       
     
freshly added:  
 
100mM PMSF (in Ethanol)  
1 Complete Mini®  
1mM Na3VO4 
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2.9.1.2. Quantification of proteins by Bradford Assay 
 
The Bradford method is a colorimetric method based on the binding of 
Coomassie brilliant blue to unknown protein. The measured absorbance of the 
unknown protein is then compared with a bovine serum albumin (BSA) standard also 
stained with Coomasie brilliant blue. The absorbance maximum of the Coomassie 
Brilliant Blue G-250 dye shifts when it binds to protein 158.  
The quantification of proteins in extracts was performed using the Bio-Rad 
reagents according to manufactures instruction. Different concentrations of BSA 
(0,25 mg/ml, 0,5 mg/ml, 0,8 mg/ml, 1,5 mg/ml and 2, 3, 4, 5, 6, 7, 8, 9 and 10 mg/ml) 
were used as standards. 2 µl of protein sample was added to 798 µl of the 1:5 diluted 
dye reagent, was mixed briefly and incubated at room temperature for 10 min. The 
absorbance was measured at 595 nm, which allowed calculation of protein 
concentration deduced from the standard BSA curve. 
 
 
2.9.2.   Characterization of proteins 
 
2.9.2.1. SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
For separation and characterization of proteins, samples were first 
denaturated in SDS-containing sample buffer and converted into polyanions. Proteins 
were then separated by electrophoresis based upon their relative molecular weight in 
denaturating SDS polyacrylamide gels 159. In this system, two gel layers were used; a 
top gel, called the stacking gel, which is slightly acidic (pH 6,8) and had a low 
acrylamide concentration to make a porous gel. Under these conditions proteins 
separate poorly, but form thin, sharply defined bands. The lower gel, called the 
separating gel, is more basic (pH 8,8), and has a higher polyacrylamide content 
(between 8 and 15%). Due to the acrylamide concentration proteins were effectively 
separated within a characteristic range. Resulting protein bands were determined by 
molecular weight marker (HighRange Rainbow Molecular Weight Marker®).  
Samples containing 25µg of protein and loading dye were heated for 5 
minutes at 95°C and were then applicated to polyacrylamide gels. Separating was 
performed between 30 and 120 mA. 
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Buffer A:   Buffer B: 
16,5g Tris-HCl, pH 8,8  46g Tris-HCl, pH 6,8 
2g SDS    2g SDS 
add 100 ml H2O 
 
Composition of separating gels: 
 
Composition of the stacking gel: 
 
 
 
 
 
 
10 x SDS-Running buffer:  
125 mM Tris, 96 M Glycine, 0,5 % SDS 
 
Compounds 8% 10% 12,25% 15% 
H2O 21,84ml 18,5ml 14,32ml 10,145ml 
Buffer A 14,8ml 14,8ml 14,8ml 14,8ml 
30% Acrylamide/Bis Solution 13,36ml 16,7ml 20,87ml 25,045ml 
10% APS 300µl 300µl 300µl 300µl 
TEMED 30µl 30µl 30µl 30µl 
Compounds  
H2O 18ml 
Buffer B 7,5ml 
30% Acrylamide/Bis Solution 4,5ml 
10% APS 225µl 
TEMED 15µl 
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2.9.2.2. Immunoprecipitation and Cdk2 kinase assay 
 
The activity of Cdk2/cyclin complexes from liver extracts was monitored in in 
vitro kinase assays using radioactively labelled ATP and recombinant histone H1 as 
a substrate under native conditions according to standard protocols 156. 500µg of liver 
protein extract in 500µl NP40 buffer was incubated with 4µl of Cdk2 antibody over 
night at 4°C performing constant agitation. The next day 25µl of protein A agarose 
beads were added and the resulting protein agarose suspension was constantly 
agitated for 1 hour at 4°C allowing binding of the protein A-beads to Cdk2/cyclin E 
complexes. Separation of the protein agarose complexes was performed by 
centrifugation at 2500 rpm for 3 minutes at 4°C resulting in formation of protein A-
agarose-antibody-antigen-complexes. After discarding of the supernatant the pellet 
was washed twice in 1ml cold NP40 buffer followed by centrifugation at 4°C with 
2500 rpm for 3 minutes. Then pellet was washed twice in histone washing buffer and 
was resuspended in 30µl of histone assay solution followed by incubation at 37°C for 
45 minutes. Every 10 minutes the solution was mixed gently and afterwards the 
reaction was stopped by addition of 6µl SDS containing loading dye. Followed by 
denaturation of the proteins at 95°C for 5 minutes and centrifugation at 14000 rpm for 
1 minute the proteins were separated by SDS-Polyacrylamide gel electrophoresis. 
Subsequent to dehydration of the gel it was analyzed autoradiographically on an x-
ray film. 
 
NP 40 buffer:   Histone washing buffer:       Histone assay solution: 
1 M Tris-HCl pH 7,5 25 mM Tris-HCl pH 7,5       5µl Histone H1  
5 M NaCl   70 mM NaCl              20 mM cold dATP 
0,5% Nonidet P-40  10 mM MgCl2       140µCi/ml 32P-γATP  
50 mM NaCl   1 mM DTT        388µl histone washing buffer 
freshly added: 
100 mM Na3VO4 
1 M DTT 
100 mM PMSF solution (in 2-propanol) 
1 Complete Mini® (Proteinase inhibitor cocktail) 
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2.9.2.3. Western Blot 
 
Western blot used for detection and characterization of specific proteins was 
performed according to standard procedures 156.  
Transfer from polyacrylamide gels to a nitrocellulose membrane was 
performed by wet blotting in a cold room at 4°C for 2 hours and a voltage of 200 mA. 
 
10x Transfer buffer pH 8,3:  
1% SDS, 20% methanol, 400 mmol/L glycine, 50 mmol/L Tris-HCl  
 
In order to control equal protein loading after SDS page and blotting, 
membranes were immersed in ponceau red solution (Stock solution: 2% Ponceau S 
in 30% trichloroacetic acid and 30% acetic acid; diluted 1:10 for use). Then, the 
membrane was rinsed in H2O until protein bands were distinct.  
Blocking was carried out in 5% nonfat milk powder and membranes were 
washed three times in TBS-0,05%Tween pH 7,6. Specific primary antibody was 
incubated over night at 4°C (diluted in TBS-0,05%Tween pH 7,6 according to the 
manufacturers instruction). After three times repeated washing, membranes were 
applied to the secondary peroxidase-coupled antibody (diluted 1:5000) and incubated 
for 1 hour. Antigen-antibody complexes were visualized on x-ray films using the ECL-
chemiluminescence kit. 
 
TBS-0,05%Tween pH 7,6:  
20 mM Tris-HCl, 4 mM HCl, 137 mM NaCl, 5,0 ml Tween 20  
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2.9.2.4. Enzyme linked immunosorbent assay (ELISA) 
 
IL-10, IL-6, IFN-γ and KC serum concentrations were determined by ELISA 
using commercial kits according to manufacturers instructions. Blood was collected 
from mice at indicated time points. After blood clotting in micro tubes (1,1 ml Z-Gel®) 
serum was collected and stored frozen. The ELISA was performed in 96-well plates, 
which were coated with capture antibody diluted in coating buffer and incubated over 
night at room temperature. The plates were then washed three times with 0,05% 
PBS/Tween-20 and after the last wash residual buffer was carefully removed. Wells 
were blocked with 10% fetal calf serum (heat inactivated) in PBS for 1 hour at room 
temperature and afterwards, wells were washed as described above. Standards and 
samples were diluted in blocking solution and incubated in wells for 2 hours at room 
temperature. Plates were washed five times with 250 µl of 0,05% PBS/Tween-20 per 
well. Biotinylated antibodies were added to the wells and were incubated for 2 hour at 
room temperature. Biotinylation of antibodies was performed according to the 
manufactures instruction. Unbound antibodies were aspirated and the wells were 
washed several (according to the individual protocols) times for 2 min each with 
PBS/0,05% Tween-20 and a dilution 1:1000 of avidin-horse-raddish-peroxidase 
conjugate (provided with the kit) in blocking buffer was added to each well and 
incubated for 30 minutes avoiding direct light. After extensive washing, the color was 
developed using tetramethylbenzidine substrate (TMB). Reaction was stopped after 
30 min by addition of 50 µl of 2 M H2SO4 to each well and absorbance was measured 
at 450 nm.  
 
Coating buffer: 
0,1M Na2CO3 pH 9,5 
8,4g/L NaHCO3 
3,56g/L Na2CO3 
freshly prepared, adjusted to pH 9,5 and stored at 4°C. 
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2.9.2.5. Myeloperoxidase (MPO) determination  
 
Quantification of MPO activity in the liver was used as an indicator of 
neutrophils infiltration.  
The whole liver was homogenized in 5 ml of 50 mM HEPES and was centrifuged at 
10.000 xg for 30 min at 4°C. Pellets were resuspended in 2 ml of 0,5% 
cetyltrimethylammonium chloride, extensively vortexed, and centrifuged at 12.000 xg 
for 15 min. The supernatant was then diluted 1:2 in 0,5% cetyltrimethylammonium 
chloride and was mixed 1:2 with the MPO substrate solution 3,3-5,5-tetramethyl-
benzidine buffer. After 15 minutes, the reaction was stopped by adding 4 N H2SO4. A 
standard curve was generated by use of purified human MPO, and activity was 
expressed in units of MPO per ml of whole organ homogenate. 
 
2.9.2.6. Determination of serum transaminases 
 
Transaminases like alanine-aminotransferase (ALT) and aspartate-
aminotransferase (AST) are enzymes catalyzing the reversible conversion of α-keton 
acids to amino acids. These enzymes are qualified as specific markers for liver 
damage. For aminotransferase analysis, animal blood was drawn. After spinning at 
200 xg, plasma was recovered and stored at -80°C until used for determination of 
aminotransferase activities.  
Enzymatic activity was determined by providing all compounds of the 
enzymatic reaction, including L-alanine/L-aspartate, α-keton glutarate, 
lactatdehydrogenase/ malatdehydrogenase and NADH2+. Expected products of the 
enzymatic reaction are L-glutamate+pyruvate and respectively L-glutamate+oxal 
acetate. Subsequent oxidation of NADH2+ to NAD+ causes dye shifts resulting in 
change of absorbance. Kinetic was measured bichromatic at 340 and 700nm. 
Measurement was performed in the clinical routine laboratories of the UK Aachen 
and the MH Hannover. 
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2.10.  Quantification of liver proliferation and histochemistry 
 
2.10.1. Hematoxylin-and-eosin (HE) staining 
 
Freshly trimmed frozen sections were first fixed in acetone for 10 minutes. For 
staining nuclei of liver cells, sections were immersed in Mayer's hematoxylin solution 
(Merck) for 8 minutes and then thoroughly rinsed in running tap water for 10 minutes 
for bluing. Counterstaining was performed with 1% eosin solution for 1 minute. 
Afterwards, dehydration was carried out in first 70% and then absolute alcohol for 2 
minutes. Slides were subsequently cleared in for more than 2 minutes and were then 
mounted in Entellan. 
 
2.10.2. Quantification of proliferation by BrdU assay 
 
2.10.2.1. In vivo BrdU labelling  
 
In vivo labelling of mouse cells was performed by intraperitoneal injection of a 
5-Bromo-2'-deoxy-Uridine (BrdU) containing solution (1mg/ml 0,9% NaCl) two hours 
before sacrificing the mice. BrdU is a thymidine analog and is incorporated into DNA 
only in mitotically active cells and can be detected by specific antibodies.  
 
2.10.2.2.  Preparation and fixation of liver sections 
 
After removal of the liver tissue frozen section were prepared and fixed for 10 
minutes in ice cold acetone/methanol (1:1; -20°C). Residues of the fixation buffer 
were removed by twofold washing procedure with TBS-0,05%Tween pH 7,6. 
Additional fixation was performed in 70% ethanol for 30 minutes at room 
temperature. Subsequently the slides were dried for 30 minutes. For blocking the 
activity of endogenous peroxidases liver sections were incubated for 10 minutes in 
0,3% H2O2/methanol. Then the slides were rinsed three times in TBS-0,05%Tween 
pH 7,6.  
 
2   MATERIAL AND METHODS 
 
 
 
51
2.10.2.3.  DNA denaturation 
 
Denaturation of DNA was performed using NaOH and formamide treatment. 
Three coplin jars were prepared in a water bath heated up to 70°C. For denaturation 
the first jar was filled with 190 ml formamide 190 ml and 10 ml of 1 N NaOH were 
added and stirred for 8 minutes. Subsequently the slides were immersed in the 
solution, incubated for 30 seconds and transferred to the second jar containing 
neutralizing solution of 190 ml formamide and 5ml 0,15 M sodium citrate. Slides were 
neutralized for 15 minutes and washed in the third jar containg heated TBS-
0,05%Tween pH 7,6. For stopping slides were rinsed twice in cold TBS-0,05%Tween 
pH 7,6 for 15 minutes at 4°C.  
 
2.10.2.4.  Supplementary fixation 
 
Additional fixation was accomplished with first 1 % formaldehyde/ TBS-
0,05%Tween pH 7,6 for 30 minutes and then with 0,2 % glutaraldehyde TBS-
0,05%Tween pH 7,6 for 10 minutes. 
 
2.10.2.5.  Detection of incorporated BrdU 
 
Slides were incubated with monoclonal anti-BrdU-antibody for 2 hours at room 
temperature (1:10000 in TBS-0,05%Tween pH 7,6). After washing twice, incubation 
with peroxidase coupled anti-mouse-Ig2-antibody (diluted 1:50 in PBS/1% BSA) was 
performed for 30 minutes. After repeated washing the enzymatic reaction was carried 
out with the substrate solution (0,5 mg DAB/phosphate buffer). Slides were then 
rinsed in water and counterstained in Mayer's hematoxylin solution and subsequently 
rinsed for 10 minutes in running tap water for bluing. 
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2.10.3.  Radioactive proliferation assay 
 
Metabolic incorporation of tritiated thymidine ([3H]-thymidine) into cellular DNA 
is a widely used protocol to monitor rates of DNA synthesis and cell proliferation 
during each cell division. [3H]-thymidine incorporated into replicating DNA is directly 
proportional to the amount of DNA synthesis and proliferation rate.  
In the present in vitro proliferation study with primary hepatocytes, cells were 
cultivated under serum free conditions over night, before stimulation was performed. 
All experiments were carried out in triplets within 6 cm wells containing 8x105 cells. 
Exactly six hours before harvest at time points indicated, primary hepatocytes were 
pulse labelled with 1µCi/ml [3H]-thymidine. For cell harvest adherent primary 
hepatocytes were washed intensively with PBS to remove excessive [3H]-thymidine.  
Subsequently cells were scraped in an appropriate amount of PBS, transferred to 
scintillation tubes containing 3 ml scintillation fluid and were subjected to scintillation 
counting. 
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3. Results 
 
3.1.  Molecular dissection of gp130-dependent pathways in 
hepatocytes determines their role during liver regeneration 
 
3.1.1. Alterations in acute phase gene regulation in genetically modified gp130 
mice after partial hepatectomy (PH) 
 
As an important mediator of liver regeneration, IL-6 has been shown in former 
studies to be involved in triggering pathways that are protective after partial 
hepatectomy 5 but only plays a minor role in directly controlling hepatocyte 
proliferation 53. Utilizing the gp130 receptor for signal transduction two major 
pathways leading to Ras/Erk or STAT1/3 activation are essential. 
In the present study gp130-dependent signalling was further dissected to the 
two individual pathways strictly limited to hepatocytes in order to understand their 
relevance during liver regeneration after PH. For this analysis hepatocyte-specific 
gp130 genetically modified mice were used either having a complete deletion of 
gp130 in hepatocytes (AlfpCre gp130LoxP/LoxP) or can selectively only activate the 
gp130-STAT (AlfpCre gp130Y757F/LoxP) or gp130-Ras/Erk (AlfpCre gp130∆STAT 
/LoxP) pathway 160. Additionally, gp130LoxP/LoxP mice were used. These mice 
express no Cre recombinase, but only carry LoxP sites in the gp130 locus and thus 
were used as wildtype control animals. 
First, the regulation of gp130-dependent pathways in these four animal strains 
were studied following PH. Analysis of the major liver derived acute phase protein in 
mice, serum amyloid A (SAA) showed a more than 150 fold induction on the RNA 
level in wildtype mice 24 hours after PH, while this regulation was completely blocked 
in AlfpCre gp130LoxP/LoxP and AlfpCre gp130∆STAT/LoxP strains. In contrast, 
compared to control mice a significant 2,5 fold stronger induction (p = 0,043) of SAA 
levels was found in AlfpCre gp130Y757F/LoxP animals after PH (Figure 7).  
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Figure 7: Regulation of the acute phase response in gp130 hepatocyte-specific modified mice 
after PH. Analysis of the major liver derived acute phase protein serum amyloid A (SAA) was 
performed by quantitative real-time PCR analysis, relative to a house keeping control gene (GAPDH). 
Compared to wildtype animals the AlfpCre gp130Y757F/LoxP mice showed a significantly higher SAA 
induction (*p = 0,04) after PH, while no expression was evident in AlfpCre gp130LoxP/LoxP and 
AlfpCre gp130 ∆STAT/LoxP animals. Data is expressed as means +/- standard deviation (SD).  
 
SOCS3 has been identified as a negative regulator of STAT3-dependent 
signalling as well as a STAT3 target gene and has an important role during liver 
regeneration 161,162. Thus its regulation in the four strains following PH was studied 
using quantitative real-time PCR analysis. SOCS3 was induced 13 fold after 6 hours 
following PH in wildtype animals. In the AlfpCre gp130Y757F/LoxP mice a 50 fold 
SOCS3 induction was evident with a maximum at 6 hours after PH (p = 0,001, 
compared to controls). In contrast, this response was completely blunted in AlfpCre 
gp130LoxP/LoxP and AlfpCre gp130 ∆STAT/LoxP animals (Figure 8). 
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Figure 8: Quantitative analysis of the negative regulator of cytokine signalling SOCS3 in the 
mutated mice strains after PH. Quantification of SOCS3 expression was performed by quantitative 
real-time PCR analysis, relative to a house keeping control gene (GAPDH). SOCS3 levels were 
significantly up-regulated in AlfpCre gp130Y757F/LoxP mice compared to wildtype mice (**p = 0,001), 
while no expression was found in the other two strains. Data is expressed as means +/- SD.  
3   RESULTS 
 
 
 
55
In addition to the study of STAT3 target genes SAA and SOCS3 the activation 
of STAT3 (p-STAT3) after PH was analyzed. Phosphorylation of STAT3 was evident 
in wildtype mice at 6 hours after PH. This signal was significantly enhanced in 
AlfpCre gp130Y757F/LoxP. In contrast, no STAT3 activation was found in AlfpCre 
gp130LoxP/LoxP and AlfpCre gp130∆STAT/LoxP mice (Figure 9). 
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Figure 9: Western blot analysis of STAT3 phosphorylation in the mutated mice strains after PH. 
For p-STAT3 analysis gels of all genotypes were run in parallel (> 4 animals per time point). P-STAT3 
expression was only detected in wildtype and AlfpCre gp130Y757F/LoxP mice. Membranes were re-
probed with anti-GAPDH (loading control). 
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3.1.2. Impact of hepatocyte-specific modulation of gp130-dependent pathways 
on hepatocyte proliferation 
 
 After studying the activation of gp130 pathways in hepatocyte-specific 
modified animals after PH, the impact of these changes on cell cycle progression 
were analyzed. Hepatocyte proliferation was quantified by BrdU pulse-labelling 
experiments. The amount of BrdU positive nuclei were determined by counting 10 
representative high power fields after microscopic examination. A maximum in DNA 
synthesis, according to maximum of BrdU positive cells was found in wildtype 
animals 40 hours after PH and a decrease in proliferation was evident at later time 
points (Figure 10).  
Wildtype
AlfpCre gp130Y757F/LoxP
AlfpCre gp130LoxP/LoxP
AlfpCre gp130∆STAT/LoxP
40h after PH 
 
Figure 10: BrdU staining of liver sections from all mice strains representing the maximum of 
DNA synthesis after PH. BrdU analysis was performed and representative microscopic photographs 
of liver sections of all mice strains are shown 40 hours after PH. Immunoreacted nuclei for BrdU were 
visualized as dark brown. Magnification x 200. 
 
A similar kinetic was detected in AlfpCre gp130LoxP/LoxP and AlfpCre 
gp130∆STAT/LoxP strains. In contrast to all other strains AlfpCre gp130Y757F/LoxP 
mice showed a different kinetic. Significantly less BrdU-positive hepatocytes were 
found 40 hours after PH and the maximum of DNA synthesis in these animals was 
evident 48 hours after PH (Figure 11).   
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Figure 11: DNA synthesis after PH in gp130-modified, hepatocyte-specific animals.  
The time plot presents proliferation kinetic of all strains after PH. Quantification of BrdU analysis 
demonstrates a delay of DNA synthesis in AlfpCre gp130Y757F/LoxP mice compared to the other 
strains. Each time point represents more than 4 animals. Very significant differences (**p < 0,01) were 
evident at 40 hours after PH between AlfpCre gp130Y757F/LoxP and wildtype mice.  
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In order to better define S-phase progression, activation of extracellular signal-
regulated kinase 1/2 (Erk1/2) was analyzed. Maximal Erk1/2 activity was found 
between 24 to 40 hours after PH in wildtype, AlfpCre gp130LoxP/LoxP and AlfpCre 
gp130∆STAT/LoxP mice. Early expression was found in AlfpCre gp130LoxP/LoxP 
mice, already at 24 hours and with maximum intensity. In contrast, the maximum in 
Erk1/2 activation was evident 72 hours after PH in AlfpCre gp130Y757F/LoxP 
animals. Expression pattern in AlfpCre gp130∆STAT/LoxP mice was almost 
comparable with control mice, but combined with weaker p44/Erk1 expression 
(Figure 12).  
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Figure 12: Immunoblot analysis of Erk 1/2 phosphorylation was performed using liver protein 
extracts. Membranes were re-probed with anti-GAPDH. Gels of all genotypes were run in parallel (> 4 
animals per time point). Erk1/2 activation was delayed after PH in AlfpCre gp130Y757F/LoxP mice 
compared to the other strains. 
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3.1.3. G1/S-phase progression is delayed in AlfpCre gp130Y757F/LoxP mice 
 
 BrdU analysis revealed a delay in start of DNA synthesis in AlfpCre 
gp130Y757F/LoxP animals compared to the three other mouse strains (Figure 4, 5). 
In order to understand differences in cell cycle progression, hepatocyte proliferation 
was studied in more detail.  
First, to characterize the entry of hepatocytes into the cell cycle, leaving their 
quiescent state, protein expression levels of cyclin D were studied. As expected, in 
wildtype mice expression of cyclin D occurred before the maximum levels of DNA 
synthesis. Strong induction of cyclin D was evident at 24 hours after PH in control 
mice. After 24 hours the expression clearly declined. Diverse alterations in cyclin D 
expression were observed in all gp130-mutated strains. Only very weak induction 
was found in AlfpCre gp130LoxP/LoxP and AlfpCre gp130Y757/LoxP mice at time 
points analyzed. In AlfpCre gp130LoxP/LoxP animals weak expression of cyclin D 
was found between 24 and 40 hours after PH, whereas in AlfpCre gp130Y757/LoxP 
mice expression was only visible between 40 and 48 hours post PH. In contrast, 
strong induction of cyclin D was evident at 24 and 40 hours after PH in AlfpCre 
gp130∆STAT/LoxP. Levels decreased at 48 hours. In all mice strains cyclin D 
expression did not exceed until 72 hours (Figure 13). 
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Figure 13: Western blot analysis of cyclin D after PH in all gp130-transgenic mice strains. In all 
strains cyclin D expression was detectable, but expression kinetics of the different strains intensely 
variegated. Membranes were re-probed with anti-GAPDH. Gels of all genotypes were run in parallel (> 
4 animals per time point). Erk1/2 activation was delayed after PH in AlfpCre gp130Y757F/LoxP mice 
compared to the other strains. 
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In order to observe G1/S phase transition mRNA expression of cyclin E1 and E2 
was quantified by quantitative real-time PCR. All gp130-modified mouse strains 
showed a peak in cyclin E1 and 2 expression 40 hours after PH. Unexpectedly, cyclin 
E1 mRNA expression was significantly higher in AlfpCre gp130Y757F/LoxP mice 
compared to the other three mouse strains studied (Figure 14).  
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Figure 14: Quantification of cyclin E1 levels after PH. 40 hours after PH significantly higher cyclin 
E1 levels were evident in AlfpCre gp130Y757F/LoxP mice compared to wildtype and AlfpCre gp130 
∆STAT/LoxP mice (*p<0,05), while significantly lower induction of cyclin E1 was found in AlfpCre 
gp130LoxP/LoxP animals (**p=0,01). Data are expressed as means +/- SD. 
 
Cyclin E2 expression levels at 40 hours after PH in AlfpCre gp130Y757F/LoxP 
mice were comparable to wildtype animals, whereas a significant reduction was 
evident in AlfpCre gp130 ∆STAT/LoxP mice and even more severe in AlfpCre 
gp130LoxP/LoxP mice (Figure 15).  
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Figure 15: Real-time PCR analysis of cyclin E2 after PH. Compared to wildtype animals 
significantly lower cyclin E2 levels were found in AlfpCre gp130 ∆STAT/LoxP (*p<0,05) and AlfpCre 
gp130LoxP/LoxP mice (**p<0,01) 40 hours after PH. Data are expressed as means +/- SD.  
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As a marker for S phase progression cyclin A was studied in all mutated mice 
strains and controls. First mRNA expression was quantified by real-time PCR. In 
control mice the maximum of cyclin A expression was evident at 40 hours. In 
contrast, AlfpCre gp130Y757/LoxP mice reached maximum cyclin A levels 8 hours 
later (Figure 16). 
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Figure 16: Quantification of cyclin A mRNA levels in all mice strains as a marker for S phase 
progression of the cell cycle.  Compared to control mice, showing maximum levels of cyclin A 
expression at 40 hours after PH AlfpCre gp130Y757F/LoxP mice had a delay of maximum levels of 
cyclin A to 48 hours. Data are expressed as means +/- SD. 
 
Next, cyclin A expression after PH was additionally studied on protein level by 
Western Blot analysis. Cyclin A expression was first detectable after 40 hours in 
AlfpCre gp130LoxP/LoxP, AlfpCre gp130 ∆STAT/LoxP and control mice (Figure 17). 
However, major differences between the strains were obvious. In wildtype mice cyclin 
A expression was detected between 40 and 72 hours after PH. In AlfpCre 
gp130LoxP/LoxP and AlfpCre gp130 ∆STAT/LoxP mice a maximum of cyclin A 
expression was detected after 40 hours. In contrast, AlfpCre gp130 LoxP/LoxP 
animals showed a significantly lower cyclin A protein expression compared to AlfpCre 
gp130 ∆STAT/LoxP animals, whereas low levels of cyclin A could still be detected up 
to 72 hours. In contrast, AlfpCre gp130Y757F/LoxP mice cyclin A expression peaked 
8 hours later although with significantly higher expression level compared to all other 
strains. In agreement with cyclin A mRNA expression data, AlfpCre 
gp130Y757F/LoxP animals showed delayed cyclin A protein expression with maximal 
levels at 48 hours after PH (Figure 17). 
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Figure 17: Western Blot analysis for Cyclin A expression after PH. As indicated in the text major 
differences in Cyclin A expression were evident between the four strains. Equal protein loading was 
assessed by re-probing membranes for GAPDH. Gels of all genotypes were run in parallel (> 4 
animals per time point).  
 
BrdU analysis and cyclin A expression levels suggested that G1/S-phase 
progression is delayed in AlfpCre gp130Y757F/LoxP animals. Therefore Cdk2 kinase 
assays were performed as the Cdk2 kinase complex plays an essential role in 
controlling transition into S-phase and DNA-synthesis 163. Maximum levels of Cdk2 
activity were found after 40 hours in all animal strains except in AlfpCre 
gp130Y757F/LoxP mice (Figure 18) where maximum Cdk2 activity was observed 
only 48 hours after PH. AlfpCre gp130 ∆STAT/LoxP mice seemed to have the 
highest Cdk2 activity at the different time points investigated.  
 
3   RESULTS 
 
 
 
63
0h    24h    40h    48h   72h
AlfpCre gp130∆STAT/LoxP
AlfpCre gp130Y757F/LoxP
Wildtype
AlfpCre gp130LoxP/LoxP
0h    24h    40h    48h   72h
0h    24h    40h    48h   72h
0h    24h    40h    48h   72h
Cdk 2
Cdk 2
Cdk2
Cdk 2
Hours after PH 
 
 
Figure 18: Detection of Cyclin-dependent-kinase 2 (Cdk2) activity. SDS-Pages of H1 Histone 
Kinase Assays of all genotypes were run in parallel (> 4 animals per time point). All strains - besides 
for AlfpCre gp130Y757F/LoxP mice - showed maximal Cdk2 activity 40 h after PH. 
 
Thus AlfpCre gp130Y757F/LoxP animals - compared to the other strains 
investigated - showed a stronger acute phase response and SOCS3 expression 
which correlated with a delay in G1-S-phase progression after PH.  
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3.1.4. Delayed proliferation in primary AlfpCre gp130Y757F/LoxP-derived 
hepatocytes correlates with higher SOCS3 expression  
 
The PH experiments in AlfpCre gp130Y757F/LoxP mice suggested that the 
delay in hepatocyte proliferation correlated with higher SOSC3 expression. In order 
to further test this hypothesis in vitro studies with primary hepatocytes from wildtype 
and AlfpCre gp130Y757F/LoxP mice were performed. The hepatocyte growth factor 
(HGF) is known to be negatively regulated by SOCS3 162,164-167 and is essentially 
needed for hepatocyte proliferation 168. Therefore, isolated cells were stimulated with 
either HGF alone or in combination with IL-6. Proliferation was monitored by 
[3H]thymidine incorporation.  
In wildtype mice 6 hours HGF treatment resulted in a significant 25% increase 
in DNA synthesis (p<0,02) (Figure 19).  
In contrast, in AlfpCre gp130Y757F/LoxP mice HGF had no major impact on 
hepatocyte proliferation, while IL-6/HGF co-stimulation inhibited DNA synthesis 6 
hours after treatment (p<0,01). However, 12 hours after IL-6/HGF stimulation 
hepatocyte proliferation in AlfpCre gp130Y757F/LoxP-derived hepatocytes was 
significantly higher in comparison to the wildtype control group (Figure 19). 
 
Wildtype 
Wildtype
AlfpCre gp130Y757F/LoxP
AlfpCre gp130Y757F/LoxP
HGF:
IL-6+HGF:
0
2
4
6
8
10
12
14
0h 6h 12h
**
**
**
Hours after Stimulation
c
pm
(x1
0 
)/1
0 
 
ce
lls
6
3
c
pm
(x1
0 
)/1
0 
 
ce
lls
6
c
pm
(x1
0 
)/1
0 
 
ce
lls
6
3
 
Figure 19: Quantification of DNA synthesis of primary hepatocytes stimulated with hepatocyte 
growth factor (HGF). For stimulation experiments including HGF only and combined HGF/IL-6 
treatment primary hepatocytes were isolated from AlfpCre gp130Y757F/LoxP and control mice. 
Primary cells were stimulated in serum free conditions the day after isolation. Quantification of DNA 
synthesis was performed by pulse labelling with [3H]thymidine. The proliferation kinetic is presented in 
a time plot. 
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HGF-stimulation alone was not sufficient to induce STAT3 phosphorylation in 
controls or AlfpCre gp130Y757F/LoxP hepatocytes. However HGF/IL-6 treatment 
significantly stimulated STAT3 activation in AlfpCre gp130Y757F/LoxP, but not in 
wildtype cells (Figure 20).  
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Figure 20: Activation of STAT3 in primary hepatocytes derived from AlfpCre gp130Y757F/LoxP 
and control mice after stimulation with HGF and in combination with IL-6. Stronger activation of 
p-STAT3 was evident after combined stimulation of IL-6 and HGF in AlfpCre gp130Y757F/LoxP 
compared to wildtype primary hepatocytes. Equal protein loading was assessed by re-probing 
membranes for GAPDH. Gels of all genotypes were run in parallel (> 4 animals per time point).  
 
These differences in p-STAT3 expression directly correlated with a 
significantly higher SOSC3 expression in HGF/IL-6 stimulated AlfpCre 
gp130Y757F/LoxP hepatocytes (Figure 21). 
4
0
1
2
3
0h 6h 12h
SO
CS
3 
m
RN
A
le
v
el
s
(fo
ld
in
du
ct
io
n
/G
AP
DH
) Wildtype 
Wildtype
AlfpCre gp130Y757F/LoxP
AlfpCre gp130Y757F/LoxP
HGF:
IL-6+HGF:
Hours after Stimulation
**
*
SO
CS
3 
m
RN
A
le
v
el
s
(fo
ld
in
du
ct
io
n
/G
AP
DH
)
 
Figure 21: Quantification of the STAT3 target gene SOCS3 after stimulation experiments of 
primary hepatocytes. SOCS-3 levels were significantly upregulated at 6 hours (**p = 0,001) and 12 
hours (*p = 0,03) after stimulation in primary hepatocytes of AlfpCre gp130Y757F/LoxP compared to 
wildtype due to stimulation of IL-6 and HGF. Data are expressed as means +/- SD. 
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3.1.5. LPS stimulation inhibits cell cycle progression after partial hepatectomy 
 
Earlier results using inducible gp130 knockout mice (MxCre gp130LoxP/LoxP) 
demonstrated that LPS stimulation following PH results in inhibition of cell cycle 
progression 53. To dissect the signalling pathways responsible for this effect, all 
mutated mice strains of the present study were subjected to LPS challenge (4 mg/kg) 
3 hours after PH. Proliferation was quantified via BrdU staining by determination of 
the amount of cells undergoing DNA synthesis. In all PH/LPS-treated mouse strains 
the maximum of BrdU positive cells could be detected 48 hours after PH (Figure 22).  
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AlfpCre gp130∆STAT/LoxP
48h after PH (+3h 4mg/kg LPS) 
 
Figure 22: BrdU analysis of all mice strains after combined challenge of PH and LPS 
application. Representative microscopic photographs of liver sections of all mice strains are shown 
48 hours after PH and LPS stimulation. Immunoreacted nuclei for BrdU were visualized as dark 
brown. Original magnification, x 200. 
 
 
In control and AlfpCre gp130Y757F/LoxP animals a maximum of 30% BrdU-
positive hepatocytes was found. In contrast, in AlfpCre gp130LoxP/LoxP and AlfpCre 
gp130∆STAT/LoxP animals, quantification of BrdU-positive hepatocytes revealed 
10% and 20% respectively (Figure 23).  
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Figure 23: Proliferation kinetic depicting all mice strains after LPS challenge presented in a 
time plot. Quantification of BrdU analysis demonstrated a maximum in DNA-synthesis in all strains 48 
h after PH with LPS stimulation. DNA synthesis was significantly reduced in AlfpCre gp130LoxP/LoxP 
(**p<0.001) and AlfpCre gp130∆STAT/LoxP mice (* p<0.05) compared to wt controls after 48 hours. 
At 72 hours higher DNA synthesis was detected in AlfpCre gp130Y757F/LoxP mice compared to 
controls (+ p<0.05). Data are expressed as means +/- SD. 
 
These results were showing a delay in DNA synthesis after LPS treatment 
(Figure 11 vs. 23). No difference in mortality was found between the four groups 
during the first 72 hours after PH (data not shown). 
 
 
3.1.6. Reduced cyclin A expression and Cdk2 activity after PH and LPS 
challenge in animals with a hepatocyte-specific deleted gp130-STAT pathway 
 
BrdU analysis indicated that LPS stimulation reduced the rate of DNA 
synthesis in the two mouse strains with a hepatocyte-specific deletion of gp130-
STAT-dependent signalling (Figure 22, 23). Next, progression of cell cycle markers in 
the PH/LPS-treated strains was analyzed.  
First, expression of cyclin D was studied on protein level in western blot 
analysis, as performed in mice exclusively subjected to PH. In general, expression of 
cyclin D occurred to be sustained and prolonged in all strains. In comparison to 
earlier experiments (see Figure 13), LPS treatment resulted in prolonged cyclin D 
expression and delayed expression peaks (Figure 24). 
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Figure 24: Cyclin D expression after PH and LPS challenge. As indicated in the text differences in 
cyclin D expression in comparison to PH only experiments were evident. Between the four strains 
changes in expression kinetics are obvious. Equal protein loading was assessed by re-probing 
membranes for GAPDH. Gels of all genotypes were run in parallel (> 4 animals per time point). 
 
Additionally, differences in cyclin E1 expression were evident between the four 
mouse strains. A maximum in cyclin E1 expression was found after 48 hours in 
wildtype, AlfpCre gp130∆STAT/LoxP and AlfpCre gp130Y757F/LoxP animals, while 
AlfpCre gp130LoxP/LoxP animals showed only very low expression levels. In AlfpCre 
gp130Y757F/LoxP mice an overall significantly (p=0,039, compared to wildtype) 
higher expression level was evident between 40 and 72 hours after PH/LPS 
stimulation. AlfpCre gp130∆STAT/LoxP and wildtype mice exhibited almost similar 
cyclin E1 expression (Figure 25). 
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Figure 25: Evaluation of quantitative real-time data of cyclin E1 analysis. Maximal cyclin E1 
expression was found 48 hours after PH/LPS challenge in wildtype, AlfpCre gp130∆STAT/LoxP and 
AlfpCre gp130Y757F/LoxP animals. Compared to wildtype mice significantly higher levels were 
evident in AlfpCre gp130Y757F/LoxP animals (**p<0.001). Data are expressed as means +/- SD.  
 
For cyclin E2 maximal mRNA levels in AlfpCre gp130Y757F/LoxP animals 
were found 40 hours after PH/LPS stimulation, which also presented a second peak 
at 72 hours after PH (Figure 26). Except AlfpCre gp130Y757F/LoxP animals all other 
strains showed a delay of maximum expression of cyclin E2 at 48 hours when 
compared to untreated animals (Figure 15). Additionally, in these mice, PH/LPS 
treatment resulted in decreased cyclin E2 expression (Figure 15). 
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Figure 26: Quantification of cyclin E2 in mice subjected to PH and additional LPS challenge. 40 
hours after PH/LPS treatment Cyclin E2 mRNA expression was significantly higher in AlfpCre 
gp130Y757F/LoxP mice compared to wildtype controls (**p<0.001). Data are expressed as means +/- 
SD. 
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Maximum levels of cyclin A mRNA levels were found at 48 hours after PH in 
AlfpCre gp130∆STAT/LoxP and control mice. In AlfpCre gp130LoxP/LoxP mice 
expression levels remained very low at 48 hours, but increased at 72 hours after PH. 
In contrast, peak of cyclin A expression in AlfpCre gp130Y757F/LoxP was found at 
72 hours after surgery and LPS challenge showing a threefold higher expression 
than expression peak of controls (Figure 27).  
 
Hours after PH 
800
0
100
200
300
400
500
600
700
0h 24h 40h 48h 72h
Cy
cl
in
A 
m
R
N
A
le
v
e
ls
(fo
ld
in
du
c
tio
n
/G
AP
DH
)
AlfpCre gp130Y757F/LoxP
AlfpCre gp130LoxP/LoxP
AlfpCre gp130∆STAT/LoxP
Wildtype
**
Cy
cl
in
A 
m
R
N
A
le
v
e
ls
(fo
ld
in
du
c
tio
n
/G
AP
DH
)
Cy
cl
in
A 
m
R
N
A
le
v
e
ls
(fo
ld
in
du
c
tio
n
/G
AP
DH
)
Cy
cl
in
A 
m
R
N
A
le
v
e
ls
(fo
ld
in
du
c
tio
n
/G
AP
DH
)
 
Figure 27: Analysis of cyclin A mRNA levels after PH and additional LPS challenge. In AlfpCre 
gp130∆STAT/LoxP mice expression levels of cyclin A after additional injury was reduced in 
comparison to mice exclusively subjected to PH (cp. Figure 16). In all mutant strains maximal 
expression of cyclin A was delayed: in AlfpCre gp130LoxP/LoxP mice maximum was found at 72 
hours, in AlfpCre gp130Y757F/LoxP mice at 72 hours and in AlfpCre gp130∆STAT/LoxP mice at 48 
hours after PH/LPS  (cp. Figure 16). Wildtype mice are showing an almost similar expression pattern 
compared to controls after PH (cp. Figure 16). A significantly stronger expression of cyclin A was 
evidenced in AlfpCre gp130Y757F/LoxP mice at 72 hours after PH/LPS. Data are expressed as 
means +/- SD. 
 
In all four groups maximal cyclin A protein expression was found after 48 
hours (Figure 27). However, significantly higher cyclin A expression was evident in 
controls as well as AlfpCre gp130Y757F/LoxP animals. In AlfpCre gp130LoxP/LoxP 
animals only very transient weak expression could be detected at the 48 hours time 
point, while in AlfpCre gp130∆STAT/LoxP mice the same expression level was 
present between 40 and 72 hours after PH/LPS challenge (Figure 28). 
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Figure 28: Western Blot analysis for Cyclin A expression after PH/LPS. As indicated in the text 
major differences in Cyclin A expression were evident between the four strains. Equal protein loading 
was assessed by re-probing membranes for GAPDH. Gels of all genotypes were run in parallel (> 4 
animals per time point). 
 
 
Next, Cdk2 activity was determined in all strains subjected to PH/LPS treatment. 
In wildtype mice, strong activity was restricted to 48 hours after PH/LPS, while in 
AlfpCre gp130Y757F/LoxP Cdk2 kinase activity was evident between 48 and 72 
hours post hepatectomy (Figure 29). Strong differences were found in AlfpCre 
gp130∆STAT/LoxP and AlfpCre gp130LoxP/LoxP animals. Only weak activity was 
evident at 48 hours after PH/LPS treatment in AlfpCre gp130LoxP/LoxP animals. In 
contrast to the other strains AlfpCre gp130∆STAT/LoxP mice showed an earlier peak 
at 40 hours after PH.  
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Figure 29: Cyclin-dependent-kinase 2 (Cdk2) activity in all gp130-mutated mice after PH/LPS.  
In order to observe Cdk2 activity, protein complexes of H1 Histone kinase assays of all mice 
genotypes were run in polyacrylamide gel electrophoresis in parallel (> 4 animals per time point). In 
wildtype animals peak Cdk2 activity was found 48 hours after PH/LPS, while minor activity was 
evident in AlfpCre gp130LoxP/LoxP. Compared to wildtypes, differences in the time kinetic were 
observed in AlfpCre gp130Y757F/LoxP and AlfpCre gp130∆STAT/LoxP mice. SDS-Pages of all 
genotypes were run in parallel (>4 animals per time point). 
 
Therefore these results suggested that LPS treatment delays start of DNA 
synthesis in all four mice strains. Additionally, lack of gp130-STAT3-dependent 
signalling significantly reduced the level of DNA synthesis. 
 
3.1.7. Acute-phase response regulation in the four mice strains after combined 
PH and LPS treatment 
 
LPS stimulation may trigger alternative pathways that are involved in 
regulating the acute phase response. Therefore, SAA mRNA expression in all mice 
strains after PH/LPS was determined. In control mice a strong increase in SAA 
expression with a maximum after 24 hours was found after PH/LPS treatment (Figure 
30). Maximum SAA expression was more than 2 fold stronger and also more 
prolonged compared to wildtype animals only treated with PH (cp. Figure 7). 
In AlfpCre gp130LoxP/LoxP animals no significant increase in SAA expression 
was observed during the first 72 hours after PH despite additional LPS stimulation. 
However, in AlfpCre gp130∆STAT/LoxP mice after 24 hours a 250 fold induction of 
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SAA was evident. This response was delayed and was first found positive at 24 
hours after surgery and LPS application. In contrast to wildtype mice, no significant 
up-regulation of SAA was found. During the first 24 hours AlfpCre gp130Y757/LoxP 
animals showed a comparable induction in SAA expression as control animals. At 
later time points SAA expression continuously increased up to 72 hours where a 
more than 600 fold SAA induction was evident compared to the pre-treatment level. 
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Figure 30: Regulation of the acute phase response in gp130 hepatocyte-specific modified mice 
after PH and additional LPS challenge. SAA quantitative real time RT-PCR showed that regulation 
in AlfpCre gp130LoxP/LoxP after PH/LPS stimulation was completely blunted, whereas in the other 
strains SAA increased during the first 24 hours after PH/LPS. In contrast to the other strains SAA 
levels further increased in AlfpCre gp130Y757F/LoxP mice up to 72 hours after challenge (‡p <0,001). 
Three up to five individual livers in each cohort at each time point following PH/LPS were examined. 
Data are expressed as means +/- SD.  
 
Next, STAT3 activation was investigated. P-STAT3 expression in the wildtype 
group was evident between 6 and 12 hours after PH/LPS treatment (Figure 31). In 
comparison to wildtype control mice exclusively subjected to PH, activation of STAT3 
was clearly prolonged and sustained after additional LPS application. Additionally, 
this regulation was stronger compared to the PH only group (Figure 9 vs. 30). In 
AlfpCre gp130LoxP/LoxP animals no p-STAT3 expression was evident. Surprisingly, 
in AlfpCre gp130∆STAT/LoxP mice weak p-STAT3 levels were found 6 hours after 
treatment. This regulation was almost similar to the changes which were detected in 
the wildtype group only subjected to PH. In AlfpCre gp130Y757F/LoxP animals after 
PH/LPS treatment strong STAT3 phosphorylation was obvious after 6 hours and in 
contrast to the other strains this regulation further increased at 12 hours (Figure 31). 
3   RESULTS 
 
 
 
74
AlfpCre gp130∆STAT/LoxP
0h 6h 12h3h1h 24h
AlfpCre gp130Y757F/LoxP
Wildtype
AlfpCre gp130LoxP/LoxP
GAPDH
P-STAT3
GAPDH
P-STAT3
GAPDH
P-STAT3
GAPDH
P-STAT3
0h 6h 12h3h1h 24h
0h 6h 12h3h1h 24h
0h 6h 12h3h1h 24h
Hours after PH (+3h 4mg/kg LPS) 
 
  
Figure 31: Phosphorylation of STAT3 analyzed in immunoblot studies of all transgenic mice 
strains after PH and LPS application. P-STAT3 levels were detected by Western blot analysis 
before and after PH/LPS treatment. Strong P-STAT3 expression was evident in AlfpCre 
gp130Y757F/LoxP mice. To check protein loading membranes were re-probed with anti-GAPDH. Gels 
of all genotypes were run in parallel (> 4 animals per time point).  
 
SOCS3 is a STAT3 target gene and is also involved in limiting gp130-
dependent STAT3 signalling. Therefore, SOCS3 expression levels after the PH/LPS 
challenge were studied (Figure 32). In control animals the kinetic of SOCS3 
expression showed a maximum 6 hours post-hepatectomy and LPS treatment. After 
this time point expression levels continuously decreased and returned to pre-
treatment levels at 48 hours. The SOCS3 kinetic was not significantly different 
compared to the results obtained from control mice in the PH only group (compare 
Figure 8). 
 SOCS3 expression in AlfpCre gp130LoxP/LoxP animals was induced only at 
low levels 6 hours after PH. Kinetic of SOCS3 expression of AlfpCre 
gp130∆STAT/LoxP and wildtype mice was almost comparable in the first 6 hours 
after PH, whereas expression occurred to be significantly enhanced at 12 hours in 
AlfpCre gp130∆STAT/LoxP mice. Strongest regulation of SOCS3 was found in 
AlfpCre gp130Y757F/LoxP animals. Peak expression was found at 6 hours with a 3 
fold higher induction compared to wildtype animals. However at 12 hours after 
PH/LPS challenge the expression levels remained high and then almost returned to 
the pre-treatment level (Figure 32). 
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Figure 32:  Quantitative analysis of the negative regulator of cytokine signalling SOCS3 in all 
strains after PH and LPS treatment. SOCS3 quantitative real time RT-PCR was performed before 
and after PH/LPS treatment. The strongest regulation was evident in AlfpCre gp130Y757F/LoxP mice 
which lasted up to 24 hours after PH/LPS treatment and was significantly higher compared to controls 
at the 6 hours time point (**p<0,001). 12 hours after PH/LPS SOCS3 expression was significantly 
enhanced in AlfpCre gp130∆STAT/LoxP animals versus wildtype mice (‡p<0,001). Data are 
expressed as means +/- SD. 
 
 
3.1.8. Oncostatin M activation in AlfpCre gp130∆STAT/LoxP animals  
 
 Unexpectedly, phosphorylated STAT3 was found in AlfpCre 
gp130∆STAT/LoxP mice after PH/LPS challenge (Figure 24), which was not 
detectable after PH only (compare Figure 9). In AlfpCre gp130∆STAT/LoxP animals 
there is still expression of the truncated gp130∆STAT receptor on hepatocytes. 
Specific members of the IL-6 family are known to initiate gp130-dependent signalling 
by dimerization with one gp130 receptor and a second gp130-related molecule. As a 
consequence, heterodimerization of these two potential molecules may activate 
intracellular pathways 169. For that reason, the truncated gp130∆STAT receptor could 
interact with one of these other receptors and as a consequence after ligand binding 
this may finally result in some activation of STAT3 in hepatocytes. Hence, the aim of 
subsequent studies was to prove, if another IL-6 family member might be induced 
after PH and LPS treatment leading to STAT3 activation in the AlfpCre 
gp130∆STAT/LoxP animals.  
 Besides IL-6, also Oncostatin M (OSM) is known to share the gp130 receptor 
subunit as the common signal transducer and show functional redundancy. Based on 
the findings of Nakamura et al., both IL-6 and OSM are able to induce full 
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phosphorylation of STAT3 cooperatively 170. Accordingly, OSM potentially may in part 
overtake this function. Therefore, quantitative RT-PCR analysis was performed for 
the IL-6 family members OSM, leukemia inhibitor factor (LIF) and Cardiotrophin 1 
(CT-1). This analysis demonstrated higher OSM expression in wildtype and in 
AlfpCre gp130∆STAT/LoxP animals. Induction in the control animals after 12 hours 
was 30 fold and in AlfpCre gp130∆STAT/LoxP animals even 130 fold, while no 
regulation was found in AlfpCre gp130LoxP/LoxP and in AlfpCre gp130Y757F/LoxP 
animals (Figure 32).  
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Figure 32: LPS treatment after PH triggers OSM expression in AlfpCre gp130∆STAT/LoxP mice. 
Analysis of OSM expression by quantitative real time RT-PCR showed significantly stronger OSM 
induction 12 hours after PH/LPS treatment in AlfpCre gp130∆STAT/LoxP animals versus wildtype 
controls (*p<0,05). No regulation was found in AlfpCre gp130LoxP/LoxP and in AlfpCre 
gp130Y757F/LoxP animals. Data are expressed as means +/- SD. 
 
 
Thus gp130-RAS-dependent signalling is associated with the induction of 
OSM after PH/LPS treatment and this response was increased when gp130-
dependent STAT signalling was impaired. Induction of the other studied IL-6 family 
members remained unaffected during PH/LPS treatment (data not shown). 
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3.2. STAT3 is required for IL-6-gp130-dependent activation of 
hepcidin in vivo 
 
3.2.1. Characterization and validation of hepatocyte-specific gp130-mutated 
mice stimulated with recombinant IL-6  
 
In order to characterize IL-6-dependent regulation of hepcidin in hepatocytes 
in vivo, gp130-modified animals were used either having a complete deletion of 
gp130 in hepatocytes (AlfpCre gp130LoxP/LoxP) or can selectively only activate the 
gp130-STAT (AlfpCre gp130∆STAT/LoxP) or gp130-Ras/Erk (AlfpCre 
gp130Y757F/LoxP) pathway. In order to characterize the modification of gp130-
dependent signalling in vivo in hepatocytes the gp130 mutant mice were stimulated 
with 250µg/kg recombinant IL-6. Livers were harvested at time points indicated. 
Before and after IL-6 stimulation activation of p-STAT3 was monitored by western 
blot analysis. In wildtype (gp130LoxP/LoxP) control mice p-STAT3 was first found 
after 3 hours and was most prominent 6 hours after IL-6-stimulation. In accordance 
with the data obtained from liver regeneration studies performing PH without LPS 
challenge (cp. Figure 9) no p-STAT3 signal was evident in AlfpCre gp130LoxP/LoxP 
and AlfpCre gp130∆STAT/LoxP mice, while stronger p-STAT3 activation was found 
in gp130Y757F/LoxP compared to wildtype animals 6 hours after IL-6 stimulation 
(Figures 34). In all animals no p-STAT1 signal could be detected after IL-6 
stimulation (data not shown). 
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Figure 34: Western blot analysis of STAT3 phosphorylation after IL-6 application in all gp130 
transgenic mice strains. According to the time points indicated expression, specific for pTyr705 of 
STAT3 was visualized by Western blot analysis using liver nuclear extracts. Equal loading of the gels 
was monitored by reprobing the membranes with an anti-GAPDH antibody. 
 
As important gp130-dependent marker genes, SOCS3 and SAA mRNA 
expression was determined in all mice strains using quantitative real-time PCR. A 
maximum in SOCS3 expression was found in controls and AlfpCre 
gp130Y757F/LoxP animals 3 hours after stimulation, while no induction of SOCS3 
mRNA could be detected in AlfpCre gp130LoxP/LoxP and AlfpCre 
gp130∆STAT/LoxP mice. SOCS3 mRNA expression was induced 50 fold in AlfpCre 
gp130Y757F/LoxP mice and was thus 4 fold higher compared to the level found in 
control animals (Figure 35).  
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Figure 35: Characterization of STAT3 dependent signalling in the hepatocyte-specific mutant 
mice subjected to IL-6 stimulation. Wildtype (gp130LoxP/LoxP), AlfpCre gp130LoxP/LoxP, AlfpCre 
gp130∆STAT/LoxP and AlfpCre gp130Y757F/LoxP mice were stimulated with 250 µg/kg IL-6.  
Quantitative real-time PCR was used to study the mRNA expression of SOCS3 before and after IL-6 
stimulation. Transcript expression in the four different mouse strains is shown as fold induction 
compared to the expression level in unstimulated animals. The RT-PCR data represent the results of 
three independent experiments. 
 
SAA expression was only induced in wildtype and gp130Y757F/LoxP mice. 
While 3 and 6 hours after IL-6 stimulation SAA mRNA expression was comparable 
between the two animal strains, its expression level was significantly higher in 
wildtype animals at the 24 hours time point (Figure 36). 
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Figure 36: Analysis of STAT3 activated expression of SAA, representing the major liver derived 
acute phase protein. All strains were stimulated with 250 µg/kg of IL-6 and SAA mRNA was 
quantified by real-time PCR. Transcript expression in the four different mouse strains is shown as fold 
induction compared to the expression levels in non stimulated animals. Data represents the results of 
three independent experiments. 
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3.2.2. STAT3 is required for IL-6/gp130 dependent hepcidin 
activation in vivo 
 
In order to dissect the molecular pathway underlying hepcidin activation in 
response to IL-6 in vivo, in all hepatocyte-specific gp130-genetically modified animals 
mRNA expression of hepcidin was determined. At different time points after IL-6 
stimulation, expression was quantified by real-time PCR. In wildtype animals 
significantly higher hepcidin mRNA expression (p = 0,001) was found 3 and 6 hours 
after IL-6 stimulation and baseline levels were found after 24 hours (Figure 36). A 
similar kinetic in hepcidin mRNA expression after IL-6 expression was found in 
AlfpCre gp130Y757F/LoxP mice showing the maximum of induction after 3 hours. 
However 24 hours after stimulation in AlfpCre gp130Y757F/LoxP animals hepcidin 
mRNA expression significantly decreased compared to the baseline level (p=0,009) 
(Figure 37). In contrast to these results no IL6-dependent regulation of hepcidin 
mRNA expression was found in AlfpCre gp130∆STAT/LoxP and AlfpCre 
gp130LoxP/LoxP animals. In the first 6 hours hepcidin mRNA expression was 
significantly different compared to the baseline level. These results indicated that IL-6 
dependent hepcidin mRNA expression is linked to gp130-dependent STAT3 
activation.  
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Figure 37: IL-6 induced hepcidin (HAMP) expression in hepatocyte-specific gp130 mutant mice. 
All strains were subjected to stimulation with 250µg/kg of IL-6 and HAMP/hepcidin expression was 
monitored by quantitative real-time PCR. The relative HAMP mRNA expression levels were 
normalized by the GAPDH signal. The data represent the results of three independent experiments.  
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To confirm the results of these experiments, Northern-blot analysis with a 
specific hepcidin cDNA probe were performed in cooperation with the Center for 
Hemochromatosis, Department of Internal Medicine of the University of Modena and 
Reggio Emilia, under the responsibility of Antonello Pietrangelo. In agreement with 
the real-time PCR data, hepcidin mRNA is stimulated at 3 hours after IL-6 injection in 
wildtype mice and AlfpCre gp130Y757F/LoxP (see lanes 2 as compared to 1 and 10 
as compared to 9, respectively), while mice with the disrupted gp130 or STAT3 
pathways failed to upregulate hepcidin mRNA (see lanes 6 as compared to 5 and 14 
as compared to 13, respectively) (Figure 38). 
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Figure 38: Northern Blot analysis of hepcidin mRNA expression after IL-6 injection. As reported, 
pooled RNA samples from 4-6 animals per group were used and the blot was first hybridized with 
hepcidin cDNA and was then re-probed with β-actin cDNA (as indicated on the left of each panel). 
Lane numbers indicate time after IL6 application: 0 hours (lanes 1, 5, 9, and 13); 3 hours (lanes 2, 6, 
10 and 14); 18 hours (lanes 3, 7, 11 and 16) ; 24 hours (lanes 4, 8, 12 and 16). 
 
To verify, that the effects observed were restricted to hepatocytes, hepcidin 
mRNA expression was also studied in primary hepatocytes derived from all animal 
strains. 24 hours after seeding hepatocytes were stimulated with 200ng/ml IL-6. 
Quantitative real-time PCR was performed at different time points after stimulation of 
primary hepatocytes (Figure 38). As observed in the entire animal, higher hepcidin 
mRNA expression after IL-6 stimulation was only observed, when gp130-STAT3-
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dependent signalling was not blunted. Hence, higher hepcidin mRNA levels were 
found in controls and AlfpCre gp130Y757F/LoxP mice, while no upregulation was 
found in AlfpCre gp130∆STAT/LoxP and AlfpCre gp130LoxP/LoxP animals (Figure 
39). In contrast to the in vivo situation hepcidin mRNA levels did not return to the 
baseline levels 24 hours after stimulation.  
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Figure 39: Evaluation of hepcidin expression in primary hepatocytes after IL-6 stimulation. 
Primary hepatocytes were isolated by collagenase perfusion from wildtype (gp130LoxP/LoxP), 
AlfpCre gp130LoxP/LoxP, AlfpCre gp130∆STAT/LoxP and AlfpCre gp130Y757F/LoxP mice and 
cultivated on 6 cm dishes. After 24 hours hepatocytes were stimulated with 200ng/ml IL-6. The 
relative HAMP expression levels were normalized by the house keeping gene GAPDH. Changes 
after IL-6 stimulation are shown as fold induction. The data represent the results of three 
independent experiments. 
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3.3. Contribution of IL-6/gp130 signalling in hepatocytes to the 
inflammatory response in mice infected with Streptococcus 
pyogenes 
 
3.3.1. Hepatocyte-specific gp130-deficient mice are more resistant to S. 
pyogenes infection 
 
In order to examine the impact of liver-specific blockage of the gp130 
signalling cascade on the course of experimental gram-positive sepsis, hepatocyte-
specific gp130-deficient mice (n=19) and wildtype mice (n=12) of FVB/n background 
were intravenously infected with 105 colony forming units (CFU) of S. pyogenes. 
Mortality due to septic shock and multiple organ failure of individual mice was 
recorded daily for 10 days. The Kaplan-Mayer-Plots (Figure 40) displayed that 
hepatocyte-specific gp130-deficient mice survived significantly longer than wildtype 
mice after S. pyogenes infection (p<0,001). Thus, while the mean survival time (MST) 
of wildtype mice was 3 days with 100% mortality at day 4 of infection, the MST of 
hepatocyte-specific gp130-deficient mice was 4,5 days with a 100% mortality at day 
8 of infection.  
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Figure 40: Survival of knockout mice and controls after S. pyogenes infection. Hepatocyte-
specific gp130-deficient mice (AlbCre gp130LoxP/LoxP, n=19) and wildtype mice (gp130LoxP/LoxP, 
n=12) subjected to S. pyogenes-induced sepsis were intravenously infected with 105 CFU of S. 
pyogenes in 0,2 ml of PBS via a lateral tail vein and survival was monitored over a period of 8 days. 
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In accordance with the longer survival, the hepatocyte-specific gp130-deficient 
mice displayed significantly lower bacterial loads in blood and systemic organs than 
wildtype mice. Maximal differences of bacterial loads in blood (Figure 41 A), liver 
(Figure 41 B) and spleen (Figure 41 C) between the gp130-deficient and wildtype 
mice were observed at 48 hours of infection by calculation of colony forming units. 
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Figure 41: Bacterial loads after S. pyogenes infection. Bacterial loads in blood (A), livers (B), and 
spleen (C) of hepatocyte-specific gp130-deficient mice (, n=11) and wild type (CTR) mice (, n=11) 
at 48 h after intravenous inoculation with 105 CFU of S. pyogenes.  
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3.3.2. Liver-specific gp130-deficient mice exhibited lower levels of 
inflammatory cytokines than wild type mice at 48 hours after bacterial 
inoculation 
 
It was previously shown, that susceptibility of mice to S. pyogenes infection is 
associated with an overproduction of pro-inflammatory cytokines such as IFN-γ and 
IL-6 171. Therefore the level of these cytokines in serum of hepatocyte-specific gp130-
deficient and wildtype mice at 48 hours after intravenous infection with S. pyogenes 
was determined. The results showed that significantly lower levels of IFN-γ (Figure 
42 A) (p<0,05) and IL-6 (Figure 42 B) (p<0,001) were present in the serum of 
hepatocyte-specific gp130-deficient mice compared to wildtype control mice after 48 
hours of bacterial inoculation. In contrast, the levels of IL-10, a gp130-independent 
cytokine, were undetectable in both wild type and hepatocyte-specific gp130-deficient 
mice after S. pyogenes infection (data not shown). Taken together, these results 
clearly indicate that blockage of gp130 signalling in hepatocytes can significantly 
attenuated the systemic inflammatory reaction taking place in septic mice after 
infection with S. pyogenes. 
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Figure 42: Quantification of pro-inflammatory cytokines after S. pyogenes infection. Serum 
levels of IFN-γ (A) and IL-6 (B) in hepatocyte-specific gp130-deficient mice (n=22) and wild type mice 
(n=12) at 48 hours after intravenous inoculation with 105 CFU of S. pyogenes. The levels of cytokines 
in serum were determined by ELISA. Each bar represents the mean value ± SD of infected samples 
over uninfected background levels. 
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3.3.3.  Disruption of gp130 signalling in hepatocytes results in 
reduced production of the cytokine-induced neutrophil 
chemoattractant (KC) 
 
It was previously shown that IL-6/gp130 engagement in hepatocytes induced 
expression and production of the chemotactic factor cytokine-induced-neutrophile 
chemoattractant (KC) 172. Therefore, we determined the levels of KC in wildtype 
control and hepatocyte-specific gp130-deficient mice at 48 hours of S. pyogenes 
infection. The results show, that while significantly high levels of KC were detectable 
in wildtype mice, levels of KC were almost undetectable in hepatocyte-specific 
gp130-deficient mice (Figure 43).  
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Figure 43: Quantification of the cytokine-induced-neutrophil chemoattractant (KC) after S. 
pyogenes infection. Serum levels of KC in hepatocyte-specific gp130-deficient (white bars) and 
control mice (black bars) at 48 hours presented after intravenous inoculation with 105 CFU of S. 
pyogenes. The levels of KC in serum were determined by ELISA. Each bar represents the mean value 
± SD of infected samples over uninfected background levels. 
 
 
This suggested, that the production of KC during S. pyogenes infection is 
primarily produced by hepatocytes in response to gp130 signalling and that KC may 
play an important role in the attraction of inflammatory neutrophils into infected 
organs. 
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3.3.4. Histopathological examination of liver tissue obtained from gp130-
deficient and wildtype control mice at 48 hours of infection with S. pyogenes 
 
In previous studies, it has been shown that general organ damage occurs in S. 
pyogenes infected mice and that liver injury and dysfunction, caused by an 
accumulation of neutrophils in this organ, contributed to the lethality in those animals. 
Histopathological evaluation of liver tissue obtained at 48 hours of infection showed a 
significantly higher number of neutrophils infiltrated into the liver of control animals 
than in hepatocyte-specific gp130-deficient animals (Figure 44).  
 
*p < 0.001
CTR AlfpCre gp130LoxP/LoxP
0
5
10
15
20
PM
N
s
/ h
ig
h 
po
w
e
r 
fie
ld
PM
N
s
/ h
ig
h 
po
w
e
r 
fie
ld
 
 
Figure 44: Accumulation of neutrophils in the liver as a scale of rating liver damage. 
Quantification of PMN infiltrated into the livers of gp130-deficient (white bars) and control (black bars) 
mice at 48 hours after intravenous inoculation with 105 CFU of S. pyogenes.  Liver tissue samples 
obtained from infected mice were fixed, embedded in paraffin and microscopically analysed. Bars 
represent the number of PMN per high power field ± SD. 
 
To substantiate the histochemical findings and to provide more quantitative 
data, the amount of myeloperoxidase (MPO), a heme protein abundantly expressed 
in polymorphonuclear neutrophils (PMNs), was determined in liver of infected 
wildtype and hepatocyte-specific gp130-deficient mice. Higher levels of MPO activity 
could be detected in the liver tissue of wildtype animals (0,9 ± 0,03 U/ml) compared 
to liver tissue of hepatocyte-specific gp130-deficient mice (0,65 ± 0,08 U/ml). The 
histological examination also showed higher numbers of apoptotic bodies in the liver 
3   RESULTS 
 
 
 
89
of control mice (Figure 45 A) than in the liver of hepatocyte-specific gp130-deficient 
mice (Figure 45 B) at 48 hours of infection.  
 
BA
 
Figure 45: Histopathological examination of liver tissue after infection with S. pyogenes. 
Representative photographes of HE-stained liver sections of control (A) and gp130-deficient (B) mice 
at 48 hours after intravenous inoculation with 105 CFU of S. pyogenes. Apoptotic bodies are indicated 
by the arrow. 
 
 
Quantification of the histopathological findings indicated that the amount of 
apoptotic bodies in the liver of infected control mice is significantly higher than in 
gp130-deficient mice (Figure 46).  
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Figure 46: Histopathological evaluation of apoptosis after infection with S. pyogenes. 
Quantification of apoptotic bodies in liver tissue of control (black bars) and gp130-deficient (white bars) 
mice. Each bar represents the mean ± SD of apoptotic bodies per high powerfield. 
 
3   RESULTS 
 
 
 
90
Histopathological differences observed in the liver of infected control and 
gp130-deficient mice correlated with the different levels of transaminases of ALT 
(Figure 47 A) and AST (Figure 47 B) detected in the serum of these animals. 
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Figure 47: Liver damage is associated with elevated levels of serum transaminases. Levels of 
ALT (A) and AST (B) in hepatocyte-specific gp130-deficient (white bars) and control mice (black bars) 
at 48 hours after intravenous inoculation with 105 CFU of S. pyogenes. Each bar represents the mean 
± SD of 10 mice per group. 
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4. Discussion  
 
4.1. Molecular dissection of gp130-dependent pathways in 
hepatocytes during liver regeneration 
 
IL-6 is involved in controlling hepatocyte proliferation and cell protection after 
PH 53,97,108. IL-6 activates intracellular pathways via the signal transducer gp130 and 
its dimerization results in phosphorylation of tyrosine residues at the intracellular part 
of the receptor 144. The aim of the present the study was to assess the role of distinct 
gp130-dependent pathways in hepatocytes during liver regeneration; two major 
pathways leading to Ras/Erk or STAT1/3 activation have been described. To 
differentiate between these two pathways in hepatocytes they were dissected by 
combining gp130 knockin mutant mice with tissue-specific gp130 knockout animals. 
Through this approach it was possible to identify gp130-dependent mechanisms in 
hepatocytes and specifically link the effect to one pathway. 
Between the strains major differences in acute phase-gene (APG) regulation 
were found after partial hepatectomy (PH). In wildtype controls transient APG 
induction was triggered after PH. This regulation was completely blocked in animals 
which lack gp130-dependent STAT3 activation in hepatocytes (AlfpCre gp130 
LoxP/LoxP and AlfpCre gp130∆STAT/LoxP mice). In contrast, APG expression was 
enhanced in AlfpCre gp130Y757F/LoxP animals, which was correlated with strongly 
upregulated levels of SOCS3. Via the second phosphorylated gp130 tyrosine the 
STAT3 target gene SOCS3 limits activation of gp130-dependent signalling pathways, 
including activation of STAT3 173. As this feedback loop is blocked in AlfpCre 
gp130Y757F/LoxP animals, prolonged STAT3 phosphorylation and significantly 
higher SOCS3 mRNA levels were evident. Unexpected, this response was 
associated with a delayed start of hepatocyte proliferation 48 hours after liver 
resection compared to 40 hours in controls. A more detailed analysis of cell cycle 
parameters demonstrated that G1/S-phase transition was also delayed in these 
animals.  
In order to further identify the potential molecular mechanisms, Erk1/2 
activation was analyzed. Erk1/2 is activated through growth factors like hepatocyte 
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growth factor (HGF) and epidermal growth factor (EGF) that are involved in triggering 
cell cycle progression of hepatocytes 162,164,166,167,174. This analysis revealed that 
specifically in the AlfpCre gp130 Y757F/LoxP animals Erk1/2 activation was delayed 
compared to the other mouse strains. SOCS3 regulation is not only linked to gp130 
and earlier results identified SOCS3 as a negative regulator of HGF and EGF 
signalling 162,164-167. These results suggested that prolonged SOCS3 activation in 
AlfpCre gp130 Y757F/LoxP animals interferes with growth factor-dependent signalling 
and as a consequence results in a delay of G1-S-phase transition 32,164,175-177.  
To further test this hypothesis primary hepatocytes were stimulated with HGF 
or HGF/IL-6. HGF resulted in an increase in DNA synthesis of primary wildtype 
hepatocytes, which was slightly reduced with IL-6 co-treatment. In contrast, in AlfpCre 
gp130Y757F/LoxP hepatocytes the impact of HGF on DNA synthesis was diminished 
and IL-6 co-stimulation significantly reduced DNA synthesis after 6 hours. Reduced 
DNA synthesis in these animals correlated with higher SOCS3 expression. Therefore 
the in vivo and in vitro experiments suggested that the strength of SOCS3 expression 
is involved in controlling DNA synthesis. 
 Several studies demonstrated no direct effect of IL-6 on cell cycle progression, 
but identified a role during recovery, survival and infection after PH 53,105,178. In an 
earlier study the effect of PH/LPS challenge was analyzed in MxCre gp130LoxP/LoxP 
mice. As described in the introduction, these mice have an ubiquitous gp130 
knockout. In contrast, in the present study the relevance of gp130-dependent 
signalling was specifically addressed in hepatocytes. In all mouse strains LPS 
injection delayed DNA synthesis to 48 hours after PH and major differences in APG 
regulation were evident. In contrast to animals exclusively subjected to PH, SAA 
expression was significantly increased in wildtype mice, while no SAA induction was 
found in AlfpCre gp130 LoxP/LoxP mice, despite PH and LPS stimulation. These 
results showed that induction of the acute phase protein SAA in mice is primarily 
regulated via gp130 in hepatocytes while other factors like LPS or TNF have minor 
impact.  
In AlfpCre gp130Y757F/LoxP mice SAA induction further increased 24 hours 
after PH/LPS. After 72 hours SAA levels were 700 fold higher compared to the pre-
treatment level. In contrast, the induction of SOCS3 lasted only until 24 hours after 
PH/LPS. In these animals - despite prolonged SAA expression - start of DNA 
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synthesis was not further delayed and was also found 48 hours after PH/LPS. 
Together with the data of PH experiments without LPS challenge and the studies in 
primary hepatocytes these results suggested that timing of SOCS3 expression is 
involved in determining the start of G1/S-phase transition after PH/LPS treatment, 
while SAA expression shows no correlation with the start of DNA synthesis. These 
results are consistent with the hypothesis that SOCS3 has an impact on timing of 
DNA synthesis most likely by interfering with growth factor-dependent signalling 
162,164,166,167,174
. 
In an earlier study using MxCre gp130LoxP/LoxP mice, resulting in efficient 
gp130 deletion in several tissues, most of the animals died after PH/LPS challenge 53. 
In contrast, AlfpCre gp130LoxP/LoxP animals survived this treatment. These results 
indicate that other cells besides hepatocytes have a major impact on survival after 
PH/LPS challenge. However, these observations together with the present study, 
where LPS-stimulated AlfpCre gp130LoxP/LoxP mice showed a dramatic reduction of 
65% in hepatocyte proliferation, further confirm the protective role of IL-6 during liver 
regeneration.  
AlfpCre gp130∆STAT/LoxP mice express a truncated gp130 receptor in 
hepatocytes that lacks docking sites required for STAT activation. IL-6 induction after 
PH was unable to trigger APG regulation. However, addition of LPS stimulated SAA 
and SOCS3 expression in these mice. APG levels were not significantly different 
compared to wildtype animals. This unexpected observation led to the hypothesis that 
LPS also triggers expression of other IL-6 family members that may use the truncated 
gp130 receptor in a heterodimeric receptor complex thereby retaining some capacity 
for STAT3 stimulation.  
The implication of OSM-mediated signalling during liver regeneration has been 
previously described 170. The present analysis showed strong OSM expression in 
AlfpCre gp130∆STAT/LoxP mice specifically after PH/LPS treatment. OSM is a potent 
activator of the Ras/Erk and the STAT pathway and in particular, OSM is induced by 
bacterial components 179. This fact may explain why AlfpCre gp130∆STAT/LoxP mice 
showed stronger DNA synthesis compared to AlfpCre gp130LoxP/LoxP animals after 
PH/LPS challenge. Thus, it is likely that ligands such as OSM trigger gp130 
heterodimerization and overcome the detrimental effect of gp130-dependent lack of 
STAT1/3 activation in these animals. 
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In summary, these results strongly suggest that gp130-dependent STAT 
signalling during liver regeneration in hepatocytes controls timing of G1/S-phase 
transition via SOCS3 thereby providing protective signals that are important to allow 
hepatocyte proliferation during stress conditions. Additionally, OSM is able to 
substitute the lack of IL-6-dependent signalling during liver regeneration. 
 
4   DISCUSSION 
 
 
 
95
4.2. STAT3 is required for IL-6/gp130-dependent activation of 
hepcidin in vivo 
 
Hepcidin is a main player in disturbances of iron homeostasis during inflammation. 
Anemia of inflammation, or anemia of chronic disease, is an acquired disorder 
commonly encountered in patients with chronic infections, malignancy, trauma, and 
inflammatory bowel diseases 180. The central pathogenic abnormality is that iron is 
not efficiently recycled from reticuloendothelial macrophages to erythroid precursors 
(leading to iron sequestration in reticuloendothelial cells), and intestinal iron 
absorption is interrupted, causing circulatory hypoferremia 181. 
These disorders were ascribed to the effect of inflammatory cytokines on iron 
metabolism. Studies in mice have shown that injections of turpentine, a standard 
inflammatory stimulus, into mice induce hepcidin mRNA 4-fold and lead to a 2-fold 
decrease in serum iron 63. The hypoferremic response to turpentine-induced 
inflammation is absent in the USF2/hepcidin- deficient mice 63 and in IL-6 knockout 
mice, 149 indicating that this response is dependent on an intact IL-6-gp130-hepcidin 
pathway. Overall, this data clearly indicated that the (IL-6 –mediated) upregulation of 
hepcidin by inflammation plays a major role in the derangement of iron homeostasis 
observed in acute or chronic inflammatory diseases. 
In the present study, the advantage of the detailed introduced gp130-mutated mice 
strains was used to dissect the signals involved in hepcidin activation by IL-6. These 
animals were first stimulated in vivo with IL-6, and the gp130-dependent signalling 
cascades were analyzed. IL-6 is unable to activate STAT1 in vivo in hepatocytes 
138,160
. However, in wildtype animals, IL-6 resulted in STAT3 activation as evidenced 
by p-STAT3 expression. STAT3 activation triggered target gene transcription of 
SOCS3 and SAA. This response was blunted in the two animal strains - AlfpCre 
gp130LoxP/LoxP and AlfpCre gp130∆STAT/LoxP - where no gp130-dependent 
STAT docking sites were expressed in hepatocytes. SOCS3 is involved in inhibiting 
gp130-dependent STAT3 activation via the Ras/Erk docking site at gp130 tyrosine 
757 26. This might be the potential reason for stronger STAT3, SAA, and SOCS3 
activation in AlfpCre gp130Y757F/LoxP mice, due to additional stimulation with 
recombinant IL-6 in combination with the inhibition of the negative feedback loop. 
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Both in vivo and in vitro data pointed to STAT3 as the key transcription factor 
responsible for IL-6-dependent activation of hepcidin gene transcription. In cultured 
hepatocytes with a disrupted Ras/Erk pathway, the response of hepcidin mRNA to IL-
6 was lower than in wildtype cells, particularly at 3 hours and 24 hours (Figure 32). 
This may suggest that Ras/Erk, at least to some extent, is also involved in the IL-6 –
dependent regulation of hepcidin. At present, this possibility cannot be ruled out. 
However, this phenomenon may be somehow related to the in vitro settings, as it 
was not found in the in vivo experiments. 
Even in vitro, it must be noted that, throughout this study, hepcidin response to 
IL-6 was consistently higher in hepatocytes with a disrupted Ras/Erk pathway as 
compared to those lacking a functional STAT3 pathway. Moreover, the central role of 
STAT3 is also supported by the results of a recent in vitro study showing that in a 
transfected hepatoma cell line, STAT3 was clearly required for response of a 0,6-
kilobase hepcidin promoter fragment to IL-6 182. Some transcription factors might be 
important for hepcidin expression: C/EBPα, SMADs, and STATs 67,183,184. C/EBPα 
knockout animals developed liver iron overload suggesting a key role of this factor in 
hepcidin control 67. More recently, a Cre-loxP mediated liver-specific disruption of 
SMAD4 involved in TGFα superfamily signalling resulted in markedly decreased 
hepcidin expression and accumulation of iron in many organs, particularly in the liver, 
kidney, and pancreas 183. Interestingly, in this study, SMAD4 knockout animals failed 
to respond to IL-6 stimulation. 
However, this interpretation is not straightforward, as other IL-6 target genes 
could be stimulated by IL-6, and the possibility exists that SMAD4 might simply 
facilitate opening of the chromatin on the hepcidin promoter. In fact, mice lacking 
hemojuvelin, a bone morphogenic protein coreceptor involved in hepcidin 
transcriptional control upstream of SMAD439 up-regulate hepcidin in response to IL-
6 185. In addition, also in view of the present results, a possible cross-talk between 
SMAD4 and STAT3 on the hepcidin promoter as shown to occur for other IL-6 target 
genes cannot be pointed out 186.  
In conclusion, although the complex interplay of different transcription factors 
and signalling molecules on hepcidin activation during IL-6 stimulus has yet to be 
clarified, the present data showed that STAT3 plays a key role in the IL-6-gp130-
hepcidin axis in vivo. 
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4.3. Contribution of IL-6/gp130 signalling in hepatocytes to the 
inflammatory response in mice infected with S. pyogenes 
 
The current study shows that blockage of gp130 receptor signalling specifically 
in hepatocytes improved the survival of septic mice lethally infected with S. 
pyogenes. Improved survival in hepatocyte-specific gp130-deficient mice was 
associated with lower bacterial burdens in systemic organs, reduced levels of the 
inflammatory cytokines IFN-γ and IL-6 and lower levels of the neutrophil 
chemoattractant KC. Hepatocyte-specific gp130 blockage also resulted in reduced 
infiltration of PMNs and lower degree of pathology. Consistent with the 
histopathological findings, biochemical markers of liver damage were also reduced in 
hepatocyte-specific gp130-deficient mice. These data together with the fact that 
eventually hepatocyte-specific gp130-deficient mice develop similar pathology to 
wildtype control mice and also succumbed to S. pyogenes infection, further 
demonstrated that the survival advantage conferred by blockage of gp130 in 
hepatocytes resulted from delay in the development of liver pathology in this 
experimental mouse model. Blockage of gp130 signalling enhanced bacterial 
clearance, decreased the expression of inflammatory cytokines, and reduced the 
infiltration of inflammatory cells in the liver. This indicates that the mechanisms 
leading to improved survival in hepatocyte-specific gp130-deficient mice may be 
multifactorial. This is not surprising since gp130 is the common receptor subunit for 
several cytokines including IL-6, IL-11, CNTF, CT-1, CLC, LIF, NPN, OSM 10 and the 
newly characterized IL-27 and IL-31 8,9. 
However, IL-6 is of particular importance since this cytokine has a pleiotropic 
effect as an inflammatory but also as an anti-inflammatory mediator during sepsis. IL-
6 has been shown to be up-regulated in human sepsis and is correlated with poor 
prognosis 172,187-189. In addition, multiple reports have demonstrated that high levels 
of IL-6 in the early phases of sepsis predict early mortality in experimental animal 
models 118-120. However, mice completely deficient in IL-6 production do not show 
improved survival in cecal ligation and puncture (CLP)-induced sepsis 190. Other 
studies have demonstrated a dose-dependent beneficial effect of IL-6 blockage in 
experimental sepsis models 191,192. These studies implied that although high IL-6 
levels may be disadvantageous during the sepsis process, but some low levels of IL-
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6 may be necessary for an appropriate acute-phase response. This underlines how 
important an appropriate control of IL-6 levels is for the outcome of sepsis. Protection 
in hepatocyte-specific gp130-deficient mice was associated with inhibition of KC 
production by hepatocytes, a chemokine that has been shown to be a differentially 
IL-6-gp130 regulated gene 193. Accordingly, it can be suggested that the harmful 
effect of high levels of IL6 may be due to the up-regulation of KC production and the 
concomitant development of liver pathology. Thus, disruption of gp130 receptor 
specifically in hepatocytes might limit the harmful effect of high levels of IL-6 during 
sepsis but will not result in a global blockage of the whole IL-6 response. 
We have also observed that ablation of the gp130 signalling resulted in 
enhanced bacterial clearance and decreased the expression of inflammatory 
cytokines. It is reasonable to assume that inhibition of gp130 signalling in 
hepatocytes might also affect the biological activity of the other gp130 family 
cytokines. In this regard, it has recently been shown that IL-27 is a key negative 
regulator of innate immune cell function during experimental septic peritonitis 194. 
Thus, in vivo blockage of IL-27 function has been shown to increase survival of mice 
subjected to CLP and enhance bacterial clearance 194. To date, nothing is known 
about the potential contribution of IL-27 to gram-positive sepsis and shock.  
In summary, this data demonstrated a major role of gp130 receptor signalling 
in modulating the inflammatory response, bacterial clearance, and organ damage in 
an experimental mouse model of gram-positive sepsis. The blockage of gp130 
signalling in hepatocytes could represent a novel strategy and adjunctive therapy for 
patients suffering sepsis.
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VI 
Zusammenfassung 
 
Mitglieder der Interleukin-6 (IL-6) Zytokinfamilie führen über den Rezeptor 
gp130 zur Aktivierung intrazellulärer Signalkaskaden, die von JAK Kinasen initiiert 
werden. Hierbei kommt es zum einen zur Induktion des Ras/Erk-vermittelten 
Signalwegs und zum anderen zur Aktivierung von STAT Transkriptionsfaktoren, 
insbesondere STAT3. 
Ziel der vorliegenden Arbeit war, die Rolle des IL-6-Rezeptors gp130 in 
Hepatozyten während der Leberregeneration, der leberabhängigen 
Eisenhomöostase sowie der gram-positiven Sepsis zu untersuchen.  
Für die hier beschriebenen Projekte wurden verschiedene gp130-mutierte 
Mausstämme generiert, die entweder einen defizienten (∆) Ras/Erk Signalweg oder 
eine blockierte STAT-Aktivierung speziell in Hepatozyten aufwiesen. Diese Mäuse 
wurden im direkten Vergleich mit einem weiteren Mausstamm eingesetzt, bei dem 
der gp130-Rezeptor in Hepatozyten deletiert ist.  
Durch die Teilresektion der Leber während der partiellen Hepatektomie (PH) 
konnte ein entscheidender Einfluss von gp130-vermittelter Signaltransduktion auf die 
Akut-Phase-Genregulation (APG) nachgewiesen werden.  
Während in gp130-∆Ras-Mäusen eine gesteigerte APG-Regulation beobachtet 
werden konnte, war die Aktivierung in gp130-∆STAT Tieren komplett blockiert. Zudem 
war in gp130-∆Ras-Tieren ein starker Anstieg der Expression des über den 
Transkriptionsfaktor STAT3-regulierten Gens, SOCS3 (suppressor of cytokine 
signalling 3) zu verzeichnen. Die verstärkte SOCS3-Expression korrelierte unmittelbar 
mit einer Verzögerung der Hepatozytenproliferation in gp130-∆Ras-Mäusen. Um die 
Assoziation zwischen erhöhter SOCS3-Expression und verzögerter Proliferation 
weiter zu analysieren, wurden primäre Hepatozyten aus den entsprechenden gp130-
mutanten Mäusen isoliert und mit IL-6 und dem Wachstumsfaktor HGF (hepatocyte 
growth factor) stimuliert. Durch die in vitro Studien mit primären gp130-∆Ras-
Hepatozyten konnte die Korrelation zwischen erhöhter SOCS3-Expression und einer 
Inhibition der Proliferation zusätzlich bestätigt werden. 
In weiteren Experimenten wurde der gp130-vermittelte protektive Effekt im 
Rahmen von Entzündungsprozessen während PH untersucht. Dazu wurden den 
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Tieren nach PH LPS injiziert. Diese Experimente zeigten in allen verwendeten 
Mausstämmen eine gesteigerte SOCS3 Expression in Verbindung mit einer 
verzögerten Zellzyklusregulation. Zusätzlich ist das Maximum der Proliferation bei 
Mäusstämmen mit blockierter STAT3-Aktivierung vermindert. Zusammenfassend 
konnte durch den ersten Teilbereich der Experimente gezeigt werden, dass STAT3 
und SOCS3 während der Leberregeneration einen entscheidenden Beitrag zur 
zeitlichen Steuerung der Hepatozytenproliferation leisten und zusätzlich einen 
schützenden Einfluss ausüben. 
Im zweiten Teil der Arbeit wurde die Regulation von Hepcidin über gp130 in 
Hepatozyten in vivo untersucht. Hepcidin wird überwiegend in der Leber synthetisiert 
und spielt eine entscheidende Rolle für die Regulation des Eisenstoffwechsels im 
Körper. Vor den Untersuchungen war bekannt, dass IL-6 eine Rolle bei der 
Regulation von Hepcidin im Rahmen von Entzündungsprozessen hat. Dabei blockiert 
Hepcidin den Transport und Transfer von Eisen aus Enterozyten und Makrophagen.  
Entsprechend wurden die oben beschriebenen Mausstämme mit IL-6 
stimuliert und die Regulation von Hepcidin untersucht. Die Ergebnisse wurden 
zusätzlich durch in vitro Experimente mit primären Hepatozyten der gp130-
defizienten Mäusen bestätigt. Übereinstimmend zeigten die in vitro und in vivo 
Studien, dass Hepcidin über gp130-STAT3 in Hepatozyten aktiviert wird, und der 
gp130-∆Ras Signalweg dabei keine Relevanz hat. 
Im dritten Teil der Arbeit wurde der Einfluss der gp130-abhängigen 
Signalwege in Hepatozyten im Rahmen der gram-positiven Streptokokken-Sepsis 
untersucht. Nach Infektion mit Streptococcus pyogenes wurden folgenden Parameter 
analysiert: Mortalität, Bakterienlast in systemischen Organen, Quantifizierung von 
Zytokinen im Serum sowie die Schädigung der Organe. 
Diese Ergebnisse zeigten, dass gp130-defiziente Mäuse signifikant länger 
überlebten, eine geringere Bakterienlast in den Organen aufwiesen und einen 
weniger progressiven Krankheitsverlauf zeigten als Kontrolltiere. 
Zudem waren die Serumkonzentrationen von IFN-γ, IL-6 und dem Chemokin 
KC in gp130-defizienten Mäusen signifikant geringer. Zusätzlich belegten 
histopathologische Untersuchungen in den Lebern der gp130 Knockout-Mäusen 
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geringere Apoptose und Infiltration von neutrophilen Zellen sowie weniger 
ausgeprägte Gewebeschädigung im Vergleich zu Wildtyp-Mäusen.   
Diese Daten zeigen, dass gp130-abhängige Signalwege in Hepatozyten die 
Entzündungsreaktion während einer gram-positiven Sepsis aktivieren, und die 
Leberschädigung durch eine Blockade von gp130 verringert werden kann. Daher 
bilden diese Untersuchungen eine mögliche Grundlage, dass eine Blockierung von 
gp130 in Hepatozyten die Basis für eine neue Behandlungsstrategie darstellen 
könnte. 
Zusammenfassend konnten die dargestellten Arbeiten zur Klärung 
physiologischer Funktionen von gp130 in Hepatozyten im Rahmen der 
Leberegeneration und Entzündung beitragen und Grundlagen möglicher 
therapeutischer Ansätze gelegt werden. 
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IX 
Summary 
 
The signal transducer gp130 initiates cellular events started by induction of JAK 
kinases resulting in Ras/Erk-mediated signalling and activation of STAT transcription 
factors, particularly STAT3.  
Within the present studies the role of the Interleukin-6 (IL-6) receptor gp130 in 
hepatocytes was investigated in terms of liver regeneration, liver dependent iron 
homeostasis and gram positive sepsis. 
Therefore, mice either defective (∆) in hepatocyte-specific gp130-dependent 
Ras/Erk or STAT activation were generated to define the role of these signalling 
pathways. These mice were used in comparison to conditional gp130 knockout mice 
having a complete depletion of the gp130 receptor in hepatocytes.  
After liver resection by partial hepatectomy (PH) the deletion of gp130-dependent 
signalling had major impact on acute phase gene (APG) regulation. APG expression was 
blocked in gp130-∆STAT animals. In contrast, gp130-∆Ras mice showed an enhanced 
APG response and a stronger expression of the suppressor of cytokine signalling 3 
(SOCS3) combined with delayed hepatocyte proliferation. In order to further elucidate the 
influence of SOCS3 during hepatocyte proliferation, primary hepatocytes were co-
stimulated with IL-6 and HGF. Confirming the in vivo observations, higher SOCS3 
expression in primary gp130-∆Ras hepatocytes also correlated with delayed hepatocyte 
proliferation.  
The aim of further studies was to analyze the protective influence of gp130-
dependent signalling on inflammatory events during liver regeneration. Therefore mice 
were additionally challenged with LPS - mimicking bacterial infection - in order to 
investigate the protective role of gp130-dependent signalling. Application of LPS in 
addition to liver resection resulted in enhanced SOCS3 expression in all animal strains in 
combination with delayed cell cycle progression. Further investigations provided evidence 
that IL-6/gp130-dependent STAT3 activation in hepatocytes plays a decisive role in 
mediating protection as well as this transcription factor is essentially required for maximal 
hepatocyte proliferation in the liver. In summary, gp130-dependent STAT3 activation and 
concomitant induction of SOCS3 during liver regeneration controls timing of DNA synthesis 
and protects hepatocyte proliferation during stress conditions. 
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Engaged in clearing up the molecular mechanisms of gp130-dependent liver iron 
homeostasis, the second part of the present work deals with the peptide hormone 
hepcidin, which is central in regulating iron metabolism. In response to IL-6, hepatocytes 
are known to produce hepcidin that decreases iron release/transfer from enterocytes and 
macrophages and causes hypoferremia.  
To clarify the molecular pathways involved in hepcidin activation triggered by IL-6, 
the different gp130-deficient mice strains were stimulated with recombinant IL-6 and 
gp130-dependent gene regulation related to hepcidin expression was studied. 
Additionally, the observations were confirmed by in vitro studies with primary hepatocytes 
isolated from the different mice strains mentioned above. 
IL-6 application in vivo resulted in induction of phospho-STAT3 and expression of 
SOCS3 and APG in livers of wildtype and gp130-∆Ras mice, whereas this response was 
completely blunted in gp130-∆STAT and liver-specific gp130 receptor knockout mice. 
In wild-type and gp130-∆Ras animals, significantly higher hepcidin mRNA 
expression was found after IL-6 stimulation. In contrast, no IL-6-dependent regulation of 
hepcidin mRNA expression was found in gp130-∆STAT and gp130 knockout mice. In 
primary hepatocytes, higher hepcidin mRNA expression after IL-6 stimulation was only 
observed when gp130-STAT3-dependent signalling was intact.  
In conclusion, this data demonstrated that both in vivo and in vitro STAT3 is the 
key transcription factor responsible for IL-6 activation of hepcidin gene expression in the 
liver. 
The aim of the third project was to study the hyper inflammatory response in 
course of gram-positive induced sepsis and whether hepatocyte-specific deletion of 
gp130 modulated the inflammatory responses.  
Sepsis and septic shock due to gram-positive bacteria have become an 
increasingly important clinical problem. These processes are accompanied by an 
overshooting inflammation in which the liver plays a central role as a source and target of 
inflammatory mediators. Despite treatment, sepsis is still associated with high mortality 
rates. New intervention strategies directed to ameliorate the extent of the inflammatory 
reaction are strongly needed.  
Hepatocyte-specific gp130-deficent mice and control mice were infected 
intravenously with Streptococcus pyogenes and the following parameters were monitored: 
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Mortality, bacterial loads in systemic organs, serum inflammatory cytokines, and organ 
damage.  
Interestingly, gp130-deficient mice survived significantly longer, displayed lower 
bacterial loads in systemic organs, and developed slower pathology than infected control 
animals. Levels of IFN-γ, IL-6 and the chemokine KC were significantly lower in gp130-
deficient mice compared to wildtype mice. Histopathological examination showed reduced 
amounts of neutrophil infiltration, apoptosis, and tissue damage in hepatocyte-specific 
gp130-deficient mice compared to wildtype animals.  
In terms of this project it was possible to demonstrate, that gp130 triggered 
signalling cascades in hepatocytes were able to impair inflammation and liver damage 
during gram-positive sepsis and that blockage of gp130 signalling in these cells might 
constitute a novel target for adjunctive therapy in septic patients. 
In summary, these projects contribute to clarify the physiological function of gp130 
in hepatocytes during regeneration and inflammation and provide basic principles of 
potential new therapeutical approaches. 
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